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Abstract
Checkpoint-inhibiting antibodies targeting CTLA-4 and PD-1, along with costimulatory agonists,
exhibit impressive anti-cancer efficacy and durable tumor regression. Despite this success,
however, many patients fail to respond because of multiple immunosuppressive mechanisms used
by cancer cells. Combination therapies designed to overcome this show promise, but strategies
relying on multiple agents face logistical and regulatory challenges, as well as increased toxicity.
This body of work begins with an in-depth review of antibody-based immunomodulatory cancer
therapy, with an emphasis on efficacy, toxicity, and their interconnectedness. Following this
background, an innovative approach to overcoming fundamental flaws in the current
immunotherapy paradigm is presented. Click chemistry was utilized to fuse two TNFR family
costimulatory agonists (anti-CD134 and anti-CD137) into a single biologic (OrthomAb) that
harnesses the immunomodulatory effects of both antibodies, essentially functioning as a “singleagent combination therapy”. OrthomAb demonstrated potent costimulatory activity in vitro and
antitumor efficacy in an aggressive mouse melanoma model. OrthomAb also elicited secretion of
several unique cytokines and exhibited unexpected, possibly beneficial, effects on T cell
proliferation. Expanding on OrthomAb as a platform revealed novel solutions to several issues

Joseph Ryan – University of Connecticut, 2020
hindering traditional combination therapy, such as the provocation of adverse events. This body
of work concludes with an overview of more recent preliminary studies aiming to unravel the
mechanism of OrthomAb, as well as that of unlinked anti-CD134 plus anti-CD137 dual
costimulation (DCo). Using CD134/CD137 single- and double-knockout mice and additional click
chemistry-derived antibody conjugates as controls, costimulatory receptor binding patterns and
hybrid signaling mechanisms are explored. Bio-engineering techniques are also discussed as a
means by which to alter the structures of antibody-derived conjugates in order to decrease toxicity
but leave efficacy intact. These mechanistic studies serve to increase our understanding of T cell
costimulation and immunomodulatory cancer therapy to inform strategies to improve upon current
treatment options. In sum, this work establishes a new framework for encapsulating the benefits
of combination tumor immunotherapy within a single agent, one which may improve treatment
efficacy and tolerability, with the ultimate goal of saving more cancer patients while also enabling
them to maintain higher quality of life.
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Chapter 1. Improving Combination Cancer Immunotherapy

This work was published in Expert Opinion on Biological Therapy, volume 16,
number 5, pages 655-674, on February 24th 2016, under the title “Enhancing the
safety of antibody-based immunomodulatory cancer therapy without compromising
therapeutic benefit: Can we have our cake and eat it too?”, authored by Joseph M.
Ryan, Jeffrey S. Wasser, Adam J. Adler, and Anthony T. Vella. Some minor
modifications to the original text were made in order to accommodate updated results
from clinical trials.
Copyright 2016. Expert Opinion on Biological Therapy 1

1. Introduction
There is an extensive list of drugs and treatment options at the disposal of clinical oncologists.
Surgery, chemotherapy, and radiation have long been the standard of care therapies for most
cancers. Nevertheless, surgery cannot eliminate highly metastatic disease, and chemotherapy and
radiation cause significant side effects due to their inability to selectively target malignant cells.
Furthermore, tumors that may initially respond to therapy often develop resistance, leading to
disease recurrence.
The identification of genetic mutations common to particular types of cancer has
facilitated the development of targeted therapies, such as the tyrosine kinase inhibitor imatinib,
which is highly effective in chronic myelogenous leukemia (CML) patients harboring the
corresponding Bcr-Abl fusion gene mutant 2. Monoclonal antibodies (mAbs) are also used in
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cancer treatment. These mAbs can be categorized into two groups based on their function.
Tumor-targeting mAbs function within the tumor microenvironment (TME), where they bind
directly to tumor cells or stromal trophic factors 3. The vascular endothelial growth factor
(VEGF) mAb inhibitor bevacizumab, for example, interferes with survival-promoting signaling
pathways important to tumor progression 4,5. The anti-CD20 mAb rituximab works by a different
mechanism, first binding to tumor cells (as well as to some healthy cells) expressing surface
CD20, then engaging innate effector mechanisms for elimination 6-9. Tumor-targeting mAbs can
also be chemically linked to radioactive or toxic entities so that the cytotoxic payload is
selectively delivered to tumor cells without harming healthy tissue 10,11.
The second group of mAbs modulate the immune system and work by promoting
tumoricidal activity in a variety of immune effector cells by lowering their thresholds for
initiating antitumor responses 12. Tumors are generally considered to be non-immunogenic since
they arise from the body’s own cells 13; thus these mAbs are in essence “breaking” peripheral
tolerance to self. These immunomodulatory mAbs can work by either antagonizing cell surface
receptors that transmit inhibitory signals (i.e., checkpoint inhibitors) or, alternatively, activating
stimulatory receptors (i.e., costimulatory agonists). The net effect in both cases is an
enhancement of tumoricidal immune effector cell activity. This chapter provides an extensive
overview of what is known about antibody-based immunomodulatory cancer therapy, with a
specific focus on therapeutic efficacy and toxicity, and then considers whether it might be
possible to optimize their design with the goal of limiting adverse events without losing efficacy.

2. Tumor immunity
The immune system constantly surveys the body for potential threats, such as pathogens, with
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the goal of neutralizing them to maintain homeostasis. The T lymphocyte (T cell) compartment
of the adaptive immune system is particularly effective at employing this “search and destroy”
strategy. Individual T cells possess exquisite specificities endowed by the expression of a unique
T cell receptor (TCR) capable of recognizing distinct peptides presented by major
histocompatibility complex (MHC) molecules on the surface of cells. Due to recombination
events between V, D, and J gene segments that comprise the TCR, the diversity of specificities is
immense, allowing for the recognition of virtually any antigen 14,15. Given the potential for many
of these TCRs to recognize self-antigens, a variety of tolerance mechanisms must be employed,
operating both centrally during thymic development 16,17, as well as in the periphery 18-21, to
prevent autoimmunity. Consequently, tumor cells, are more difficult to detect since the majority
of their antigens overlap with those expressed in their healthy progenitors to which T cells have
already been tolerized. In some cases, vaccination against these non-mutated tumor-associated
antigens (TAAs) can elicit effector T cells that simultaneously mediate tumor immunity and
autoimmunity 22-24. Alternatively, the genetic instability characteristic of malignant cells 25,26
gives rise to mutations in protein-coding genes, resulting in the formation of tumor-specific
(neo)-antigens (TSAs) that can be targeted by T cells without causing autoimmune disease 27,28.
Naïve T cells are activated when they encounter cognate peptides complexed to MHC
molecules on the surface of antigen-presenting cells (APCs). This event, referred to as “signal
1”, is the first of three sequential signals required to program proliferation, differentiation, and
survival. Dendritic cells (DCs) represent the most potent APC population, in part owing to their
efficiency in capturing and processing antigens into peptide fragments suitable for MHC
presentation. Upon sensing pathogen-associated molecular patterns (PAMPs), DCs are also
induced to express costimulatory ligands and pro-inflammatory cytokines, delivering signals 2
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and 3, respectively 29-31. Costimulation occurs in two waves. First, the immunoglobulin (Ig)
superfamily molecules CD80 (B7.1) and CD86 (B7.2) on DCs ligate CD28 on the antigenresponding T cells to facilitate the initial phase of activation 32-34. Tumor necrosis factor receptor
(TNFR) superfamily members then deliver a second costimulatory wave. This process fine-tunes
T cell responses by regulating the magnitude of clonal expansion, determining which particular
cytokines the T cells become capable of secreting, and dictating whether long-lived memory is
established 35,36. The cytokines that constitute signal 3 further contribute to fine-tuning the T cell
response 37.
In the absence of inflammation, however, steady-state DCs express only minimal
amounts of costimulatory ligands and cytokines. Under these conditions, T cells encountering
cognate antigens (e.g., self-antigens acquired from healthy tissues by DCs) undergo an
abortive/tolerogenic response 38-40. This process not only serves to prevent autoimmunity
mediated by self-reactive T cells that escape negative selection in the thymus 41, but also can
dampen tumor immunity by tolerizing T cells specific for TAAs 24,42 and TSAs 43,44. A critical
factor in programming effective antitumor T cell responses is the amount and variety of
costimulation and cytokines accompanying DC presentation of tumor epitopes. The PAMPs that
help facilitate the potent activation of DCs during infection are generally absent from tumor
sites, often resulting in a tolerogenic outcome (as described above). Nevertheless, productive T
cell responses to tumor antigens do occur in some cases 45-47. DC activation can be achieved
when tumor cells undergoing certain forms of programmed death 48 release damage-associated
molecular patterns (DAMPs), such as heat shock proteins 49, uric acid 50 and HMGB1 51, which
can act in a manner analogous to that of PAMPs.
Even when tumor-reactive T cells are successfully primed, with the capacity to migrate
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into tumors and kill target cells, the efficiency and overall impact of the response can be
inadequate. In a process termed “immunoediting”, the most immunogenic tumor cell variants are
eliminated during the initial stages of tumorigenesis, while less immunogenic tumor cells are
spared and gradually expand 52. Whether T cells become tolerant of tumor antigens at the earliest
stages of tumorigenesis due to a lack of DC activation, or alternatively following a period of
immunoediting, clinically detectable tumors are inherently non-immunogenic. Furthermore, the
resulting non-immunogenic tumor engages a variety of powerful immunosuppressive
mechanisms that can thwart the activity of infiltrating effector T cells and foster a tumorfavorable microenvironment. For example, the recruitment of regulatory T cells (Tregs) 53-56 and
myeloid-derived suppressor cells (MDSCs) 57 establishes an immune barrier around tumor sites,
effectively protecting malignant cells from immune intrusion. Additional mechanisms include
the secretion of immune-regulating cytokines such as transforming growth factor beta (TGF-)
58,59

and enzymes such as indoleamine 2,3-dioxygenase (IDO) 60, all of which are capable of

altering the immune response within the TME.
An understanding of the mechanisms underlying tumor-induced immunosuppression is
paramount to the development of effective cancer therapies, and as such has become a major
focus of investigation; a comprehensive review on the subject is provided by Rabinovich and
colleagues 61. To be effective, T cell-based immunotherapies will likely need to compensate for
insufficiencies during the initial phase of T cell priming, as well as confer the capacity to
overcome potent immunosuppression within the tumor microenvironment. Therefore, the most
effective cancer therapies will likely consist of multiple agents targeting a variety of cancerpromoting pathways and mechanisms. Combination therapies have already begun to showcase
their clinical potential, in some cases demonstrating enhanced efficacy and superiority over
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standard of care monotherapies. Although combining multiple agents can cause more frequent
and severe adverse events, increases in efficacy may exceed increases in toxicity, suggesting
combination approaches as one possibility for improving safety without sacrificing therapeutic
benefit.

3. Checkpoint inhibitors
The immune system prevents excessive inflammation or autoimmunity via the engagement of
inhibitory feedback networks. A commonly used analogy equates the immune system to an
automotive vehicle with the antigen-stimulated TCR representing the transmission in drive,
CD28 costimulatory receptor acting as the accelerator, the TNFR costimulators functioning as
turbo boosters, and checkpoint inhibitory receptors serving as the brake.
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) was the first checkpoint receptor
identified and is the most extensively studied. Following the initial activation of naïve T cells, in
which DCs provide signal 1 (MHC-peptide) along with signal 2 in the form of B7.1 and B7.2
ligating CD28, intracellularly stored CTLA-4 is relocated to the T cell surface where it competes
with CD28 for binding to B7.1 and B7.2 62, thereby helping to avoid excessive CD28-mediated
stimulation. Upon ligation, CTLA-4 engages the protein phosphatases SHP2 and PP2A, which
deactivate signaling proteins downstream from TCR engagement 63. The net effect is the
prevention of T cell hyper-responsiveness 51,64-67.
Mice harboring a null mutation in the gene encoding CTLA-4 develop fatal
lymphoproliferative disease characterized by autoreactive T cell infiltration and extensive tissue
destruction 68. This dramatic phenotype results not only from the predicted effect of releasing the
brakes on self-reactive T cells, but also from impairment in the function of Tregs, which
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constitutively express surface CTLA-4 to maintain tolerance and suppress auto-reactivity 20,69-73.
That CTLA-4 functions on multiple cell types to maintain immune homeostasis raised the critical
question of whether it could be targeted therapeutically without unleashing fatal adverse events.
Nevertheless, preclinical studies using a variety of mouse tumor models demonstrated that a
blocking mAb to CTLA-4 altering the activities of both tumor-reactive effector T cells and Tregs
can produce therapeutic benefit, albeit with toxicity 74-78.
This work paved the way for the development of a humanized CTLA-4 antagonist,
ipilimumab 79. A decade of clinical trials culminated in an international phase III trial that led to
its 2011 approval by the FDA for treating melanoma, making it one of the first immune-based
biologic therapies, and the first checkpoint inhibitor, to be used clinically 80. In this study, 676
patients with late-stage melanoma were given either ipilimumab, a vaccine targeting the
melanoma TAA gp100, or ipilimumab plus vaccine. Objective response rates (ORR) for
ipilimumab alone and gp100 alone were 10.9% and 1.5%, respectively. Importantly, ipilimumab
(with or without vaccine) boosted median overall survival (OS) by 10 months, compared to 6.4
months for gp100 vaccination alone (Table 1.1). These encouraging results earned for
ipilimumab its approval for the treatment of unresectable or metastatic melanoma.
Another checkpoint molecule, programmed cell death protein 1 (PD-1), is expressed
primarily on already-activated effector T cells and regulates their activity in the periphery 81,82.
Upon binding of its ligands, PD-L1 83 or PD-L2 84, PD-1 engages phosphatases that inactivate
signaling molecules downstream of the TCR to limit proliferation, survival, and cytokine
production 85. PD-1 is highly expressed on CD8+ T cells residing within the TME 86. PD-L1 can
be constitutively expressed by tumor cells 87,88 due to oncogenic signaling pathway aberrations
89,90

or induced in response to localized T cell secretion of cytokines (e.g., interferons) 91-93 in a
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process referred to as adaptive immune resistance 94. Tumor-infiltrating myeloid cells and
lymphocytes can express PD-L1, and their co-localization and interaction with PD-1-expressing
cells further define PD-1-mediated activity within the TME 95,96. PD-1 also plays a role in Treg
function 97, and thus, similar to CTLA-4 blockade, targeting the PD-1/PD-L axis may enhance
tumoricidal capacity through effects on both effector and regulatory T cells. Indeed, preclinical
testing in mouse models demonstrated that mAb-mediated disruption of PD-1/PD-L1 interaction
can boost tumor immunity 98,99.
Two humanized antagonist mAbs targeting PD-1, pembrolizumab and nivolumab, have
been approved after yielding significant therapeutic responses in phase III clinical trials 100-102. A
double-blind phase III trial of 418 patients receiving either nivolumab or dacarbazine found ORR
of 40.0% and 13.9%, respectively, and 1-year OS rates of 72.9% and 42.1%, respectively 103
(Table 1.1). Response to treatment has also been shown to correlate with tumor expression of
PD-L1 100. Additional clinical data show similarly encouraging therapeutic responses in patients
treated with anti-PD-L1 mAb 104, and provide preliminary evidence in support of using
intratumoral PD-L1 expression as a biomarker to determine likelihood of therapeutic success on
a patient-to-patient basis 95,96,105,106.
Checkpoint-inhibiting biologics are now being used routinely to treat patients with
malignant melanoma, and numerous ongoing clinical studies raise the likelihood that they will
soon be approved for treating patients with a variety of cancers including kidney, bladder,
prostate, and lung 79. Recently, nivolumab was approved for additional indications including
non-small cell lung carcinoma (NSCLC) and renal cell carcinoma (RCC). Thus, in addition to
the durability of treatment response, the potential for use in a number of different clinical
conditions sets these mAbs apart from other oncologic agents. As shown in Table 1.1,
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checkpoint inhibitors and costimulatory agonists have demonstrated efficacy in both solid tumors
and hematologic malignancies 107. Particularly noteworthy is their efficacy in solid tumors,
which can be especially difficult to treat due to the existence of localized immunosuppression in
the TME 53-60. Intriguingly, immunomodulatory mAbs enable antitumor activities that are
relatively nonspecific with respect to cancer subsets, but relatively specific in terms of
preferential targeting of cancerous cells while for the most part sparing healthy cells, in essence,
approaching the “holy grail” of cancer therapy.
mAbs blocking both CTLA-4 and PD-1/PD-L1, enhance tumor immunity by disrupting T
cell inhibitory signaling. However, they act during distinct early (CTLA-4) and late (PD-1)
phases of the anti-tumor response. Thus, the possibility is raised that a combination therapy
might be superior to either agent alone. Improved response has been confirmed in mice 108, and
human data obtained thus far have been encouraging. In one study the combination of nivolumab
and ipilimumab given concurrently yielded objective clinical responses 109 exceeding those
reported previously for either monotherapy 80,100, although direct comparison was not made.
While objective-response rates may not predict long-term benefit to patients, and survival data
are needed, these early studies suggest a potential advantage of combination treatment strategies
109

.
A phase III study 106 comparing nivolumab alone, ipilimumab alone, and combination of

the two, in previously-untreated metastatic melanoma (major findings highlighted in Table 1.2),
demonstrated greater progression-free survival (PFS) for nivolumab, alone or in combination
(both 14.0 months), compared with ipilimumab alone (3.9 months). Notably, in the context of
PD-L1-positive tumors, the addition of ipilimumab to nivolumab did not improve PFS but did
increase the overall rates of grades 3/4 adverse events, from 43.5% to 68.7%. In this case it
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would appear that combination therapy is not as safe as nivolumab monotherapy (Table 1.2).
However, combination therapy had greater efficacy than either monotherapy in the context of
PD-L1-negative tumors (Median PFS of 11.2 months, compared to 5.3 months and 2.8 months
for nivolumab and ipilimumab, respectively). Although the advantage over nivolumab
monotherapy dissipated by 16 months of treatment (not shown in Table 1.2), these data speak to
the value of combined therapy regimens 106.
Although this study showed no evidence of synergy, the additive effects of combination
therapy seen with PD-L1-negative tumors provides some evidence that this multi-pronged
approach may offer unique advantages over single-agent therapies in some tumor types.
Nonetheless, definitive conclusions from this study regarding the value of supplementing
nivolumab with ipilimumab cannot be drawn until overall survival (OS) data are obtained.
After original publication of this review article, the 3-year update of this study found that
ORR remained steady. 3-year PFS rates for ipilimumab treatment, nivolumab treatment, and
nivolumab + ipilimumab treatment were 10%, 32%, and 39%, respectively. 3-year OS rates
were: ipilimumab (34%), nivolumab (52%), and nivolumab + ipilimumab (58%). 3-year median
OS were: ipilimumab (19.9 months), nivolumab (37.6 months), and nivolumab + ipilimumab
(not yet reached) 110. A summary of these updated data and more can be found in the second part
of Table 1.2.

4. Costimulatory agonists
Agonist mAbs targeting costimulatory receptors on antigen-primed T cells represent the second
major category of immunomodulatory antibodies. Primarily targeting receptors of the TNFR
superfamily that provide the second wave of signal 2, these antibodies are designed to mimic the
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activity of endogenous costimulatory ligands whose availability tends to be low in the context of
tumor antigen presentation. In contrast to Ig superfamily costimulatory receptors such as CD28
that modulate activity of signaling proteins located proximally to the TCR, TNFR superfamily
costimulatory receptors engage various combinations of TNFR-associated factors (TRAFs) 1-6,
which control several downstream signaling pathways that include NF-B and MAP kinase 35,36.
CD40 is a TNFR family member expressed on DCs that, when bound by its ligand
CD40L (CD154) expressed on cognate CD4+ helper T cells, induces expression of MHC
molecules, costimulatory ligands (B7.1 and B7.2) and cytokines such as IL-12, which
collectively function to boost the response of CD8+ cytotoxic T lymphocytes (CTL) 111-114. A
CD40 agonist mAb can thus activate DCs when CD4+ T cell help is unavailable and lead to
robust effector T cell responsiveness and antitumor immunity 115-117.
Agonists can also directly target TNFR costimulatory receptors on T cells. For instance,
CD134 (OX40) expressed on T cells following TCR stimulation 118,119 can be ligated by OX40L
(CD252) expressed on activated, but not steady state, DCs 120 to program T cell effector
differentiation, survival, and memory 119,121-123. CD134 agonist thus enables antigen-primed T
cells to develop potent effector and tumoricidal capacity under otherwise tolerogenic (i.e., steady
state) conditions 124-131. Similarly, T cell responsiveness and tumor immunity in mice can also be
elicited with agonists to several other T cell TNFR family costimulatory receptors such as
CD137 (4-1BB) 132, glucocorticoid-induced TNFR-related protein (GITR) 133 and CD27 134.
Extensive mouse studies characterizing the therapeutic potential of TNFR agonists have
fueled ongoing efforts to develop humanized therapeutics. Although clinical testing of these
agents has lagged behind that of the checkpoint inhibitors by several years, initial results for
costimulatory agonists have been encouraging. For instance, a phase II trial evaluating the CD40
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agonist dacetuzumab for use in the treatment of relapsed diffuse large B-cell lymphoma
demonstrated clinical benefit in a subset of patients 135, complementing previous data from phase
I testing of this agent in other cancers, which found only moderate toxicities associated with
therapy 136-138. For example, one study demonstrated that out of 44 patients with multiple
myeloma treated with dacetuzumab, adverse events of mild cytokine release syndrome, noninfectious ocular inflammation, and elevated liver enzymes were infrequent and well tolerated,
with less than 10% experiencing serious toxicities 138. Additional phase I trials evaluating
dacetuzumab in other cancers such as non-Hodgkin’s lymphoma (NHL) 136 and chronic
lymphocytic leukemia (CLL) 137 have generated similar results.
CP-870,893, a fully-human IgG2 mAb considered to be a more potent anti-CD40 agonist,
has yielded relatively encouraging efficacy data, including a phase I ORR of 20% in combination
with carboplatin and paclitaxel to treat various advanced solid tumors 139 (Table 1.1) and another
phase I ORR of 19% with 4 partial responses (PRs) in combination with gemcitabine to treat
advanced pancreatic ductal adenocarcinoma (PDA) 140, with generally tolerable side effects. CP870,893 has since been licensed to Roche and is now, under the name RO7009789, undergoing
phase I testing in patients with locally advanced and/or metastatic solid tumors and newly
diagnosed resectable PDA.
Alternatively, a mouse mAb agonist specific for human CD134 given in a phase I trial to
patients with various advanced cancers elicited objective clinical responses (regression of at least
one tumor nodule) in 12 out of 30 patients 141 (Table 1.1). Although none of the patients
demonstrated responses according to Response Evaluation Criteria in Solid Tumors (RECIST,
tumor shrinkage of at least 30%), the fact that these results were achieved using a murine mAb
that could only be given in a single course (due to the production of human anti-mouse
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antibodies (HAMA) in patients) is highly encouraging as it suggests that fully humanized CD134
agonists might elicit significant tumor regression, especially if given in multiple courses. A
humanized CD137 agonist urelumab has also demonstrated therapeutic activity in phase I testing
142

, although liver toxicities led to the termination of phase II testing (Table 1.1). It was later

determined that the toxicities that had occurred were dose-dependent, and careful dosing of the
agent could avoid liver damage. Humanized agonists to other TNFR members are currently in
various stages of clinical development 143-145.
Given the possibility that a variety of humanized TNFR agonists may gain FDA approval
for the treatment of human cancer patients, it would be useful to consider if they might be
combined to improve therapeutic efficacy, like the checkpoint inhibitors 108,109. The rationale for
combining agonists targeting different TNFR family members stems from their non-identical
tissue expression patterns as well as the partial (but not complete) overlap in the signaling
pathways they engage. These subtle differences likely reflect the potential of each member to
uniquely contribute to the fine-tuning of T cell responses needed to optimally handle particular
immunogenic challenges 35,36. In a clinical setting, it might be possible to exploit this variation
by combining particular TNFR agonists to tailor optimal antitumor responses 146. For instance,
co-administration of agonists to CD134 and CD137 147-151 or death receptor 5 (DR5, also known
as TRAIL receptor 5) plus CD40 and CD137 152 can be synergistic in programming T cell clonal
expansion and effector function enabling the control of tumor growth in mice. Effective
combination strategies might also involve the administration of a checkpoint inhibitor with a
TNFR agonist, as has been demonstrated with anti-CTLA-4 plus anti-CD137 153 and also with
anti-PD-1 plus anti-CD134 154.
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5. Adverse events
The elicitation of adverse events is a risk inherent to virtually any type of therapy. With immunebased therapies, adverse events can potentially involve several mechanisms, which vary
depending on the particular nature of therapy. For example, therapeutically-administered
cytokines can give rise to nonspecific, systemic immune reactivity due to their widespread sites
of action, whereas other immunotherapies such as adoptive cell therapies, tumor vaccines, and
immunomodulatory antibodies tend to trigger more localized tissue destruction due to their more
targeted and specific immune cell activation 155. With immunomodulatory mAbs, tumoricidal
effector T cells that recognize non-mutated TAAs can destroy healthy cells expressing that same
TAA. The classic example of this type of immune-related adverse event (irAE) is vitiligo, in
which T cells primed to non-mutated melanocytic antigens destroy both melanoma cells and
healthy melanocytes 23,156. While vitiligo may be an acceptable trade-off for clearing aggressive
melanomas (and other cancer types), autoimmune disease obviously would be more problematic
when treating tumors derived from vital organs.
Another mechanism leading to irAEs is the disengagement of inhibitory pathways critical
for maintaining tolerance to self and immune homeostasis. For instance, since part of the overall
mechanism by which ipilimumab boosts tumor immunity involves neutralizing the function of
Tregs 76,78, it might be expected that ipilimumab-treated patients would experience irAEs that
would otherwise be kept in check by Treg oversight. Consistent with this prediction, in the
landmark melanoma phase III clinical trial mentioned previously, 60% of ipilimumab-treated
patients experienced irAEs, 10-15% of which were severe (grades 3/4) that included diarrhea,
vitiligo, colitis, and endocrinopathies, as well as infusion reactions 80 (Table 1.1). Careful
examination of the specific mechanism(s) involved for individual antibodies (shown for a
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representative sample of mAbs in Table 1.4) can also shed light on how specific toxicities arise
due to therapy. For example, because anti-CTLA-4 works, in part, by depleting Tregs and/or
altering their function, the occurrence of diarrhea, colitis, and other gastrointestinal (GI)
manifestations can be attributed to the abundant Treg populations located in the GI tract and their
critical role in maintaining immune tolerance 157. Tissue-specific and antibody-specific adverse
events are discussed in greater depth elsewhere 12.
In contrast, irAEs caused by targeting the PD-1 axis tend to be fewer in frequency and
less severe 100,101,104. Early human testing revealed tolerability of adverse events in addition to
impressive efficacy, with response rates ranging from 18-27% when used to treat NSCLC, RCC,
and melanoma, with grades 3/4 adverse events occurring in 14% of patients 100. Adverse events
observed during anti-PD-1 therapy have included hepatitis, colitis, hypophysitis, thyroiditis,
pneumonitis, and vitiligo (Table 1.1). Antibodies targeting PD-L1 have demonstrated response
rates and safety profiles comparable to those targeting PD-1 104. This difference in adverse event
profiles, along with the fact that PD-1 blockade can be effective in ipilimumab-refractory
melanoma 109, suggest that these particular checkpoint inhibitors act via distinct cellular and
molecular mechanisms. PD-1/PD-L1 interactions primarily take place peripherally at sites where
activated T cells interact with PD-L1/2-expressing cells (e.g., within the TME), whereas
B7/CD28/CTLA-4 interactions occur primarily in lymphoid organs 158 harboring bountiful
populations of T cells, and Tregs in particular (e.g., Peyer’s patches in the lining of the small
intestines). Thus, the action of mAbs targeting PD-1 are likely concentrated within the TME as
opposed to anti-CTLA-4 mAbs, manifesting in a decreased likelihood of off-target effects and
greater tolerability.
Combination therapies targeting CTLA-4 and PD-1 have generated positive data showing
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that combining immunomodulatory mAbs might have advantages over either monotherapy,
albeit with greater side effect frequency and severity. The phase 3 study discussed previously
and outlined in Table 1.2 found that combination of nivolumab plus ipilimumab, compared with
nivolumab alone, resulted in a greater incidence of grades 3/4 adverse events (68.7% versus
43.5%, respectively 106). The 3-year follow-up report revealed an even larger gap in severe
adverse events between nivolumab + ipilimumab (59%) and nivolumab alone (21%); severe
adverse events with ipilimumab alone occurred at a rate of 28% 110 (Table 1.2). There were no
drug-related deaths seen with combination therapy, and most adverse events (85-100%) could be
managed successfully using standardized treatment guidelines, including steroids and infliximab
106,110

, but endocrine-related events were the most resistant to management. Thus, combined

therapy targeting CTLA-4 and PD-1 might be advantageous in subsets of patients determined by
screening for the presence of predictive biomarkers, such as tumor PD-L1 expression.
Differences among checkpoint inhibitors are also reflected in their dosing regimens
(outlined in their respective package inserts). For the treatment of melanoma, ipilimumab, for
example, is given every 3 weeks for a total of four doses, at which point therapy must be
stopped. On the other hand, nivolumab, with its milder side effect profile, is given every 2 weeks
indefinitely, until the patient experiences either lack of clinical benefit or unacceptable toxicity.
Nivolumab can also be combined with ipilimumab, with the two agents being co-administered
every 3 weeks for 4 doses, after which point the normal dosing scheme of nivolumab is followed.
Importantly, nivolumab is also indicated for NSCLC and RCC. Pembrolizumab, the other
approved PD-1 antagonist, is currently indicated for melanoma and NSCLC, and is given every 3
weeks. For either anti-PD-1 therapy, treatment is maintained regardless of whether the tumor
completely resolves or its size has stabilized. Thus, a major advantage of anti-PD-1 mAbs is
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greater tolerability, making them more suitable for maintenance therapy in appropriate patient
subsets.
Costimulatory agonists might be expected to elicit irAEs associated with the production
of inflammatory mediators that drive T cell expansion and effector differentiation, but on the
other hand also have potential toxic properties when present in large quantities systemically. For
instance, CD40 ligation on DCs induces secretion of IL-12 111, which facilitates beneficial
tumoricidal effector T cell function 159, but when present at high systemic levels can be toxic 160.
Perhaps the most dramatic example of this type of irAE occurred during a phase I clinical trial
evaluating the safety of TGN1412, a superagonist to CD28 that had been designed to activate
Tregs, but unfortunately ended in disaster when all six trial participants in the treatment group
rapidly developed symptoms characteristic of cytokine release syndrome (cytokine storm
involving rapid spikes in systemic TNF-, IFN-, IL-6, IL-2, IL-1 and others, as illustrated in
Figure 1.1), such as headache, nausea, diarrhea, vasodilation, hypotension, and eventually (nonfatal) multi-organ failure 161.
Several mechanisms have been suggested for cytokine release induced by TGN1412. One
viewpoint implicates a toxic inflammatory response due to T cell hyper-activation mediated by
excessive costimulatory receptor stimulation (depicted in Figure 1.1B, in this case using CD137
as a representative example) 162,163. Another school of thought points to excessive activation of
innate effector cell populations (e.g., monocytes and NK cells) via antibody fragment
crystallizable (Fc) engagement of Fc receptor (FcR) (discussed in the next section), thus
triggering the massive release of pro-inflammatory cytokines 164,165 (Figure 1.1C). Although the
severe symptoms elicited by TGN1412 were impossible to predict, it was already known that
infusion of immune-reactivity antibodies can trigger responses resembling cytokine release
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syndrome 166-168. It is likely that both mechanisms were, at least to some extent, involved in
mediating toxicity in these patients. Evidence supporting the latter assertion comes from recent
work describing contributions of stimulation-induced FcR signaling to the induction of proinflammatory cytokines 169,170, in addition to the suggested role of pro-inflammatory M1
macrophages in mediating immunotherapy-associated toxicity 171.
In the case of the anti-CD137 agonist urelumab, phase II testing had to be terminated due
to unanticipated severe toxicity in a substantial portion of patients. Grade 4 hepatitis was the
most serious adverse event, although additional toxicities were commonly noted, including
fatigue, rash, diarrhea, and neutropenia (Table 1.1). These toxicities may have been related in
part to the production of pro-inflammatory cytokines, such as types I and II interferons (IFN) and
tumor necrosis factor alpha (TNF-) 107,142. These results were perhaps not entirely surprising
since mouse studies have demonstrated that CD137 agonist administered chronically or at high
dosage can induce immunologic dysfunction leading to organ-specific toxicities that correlate
with increased CD8+ T cell infiltration into those tissues and organs 172,173. Subsequent clinical
testing of CD137 agonists has utilized modified protocols with lower dosages, avoiding the dosedependent hepatotoxicities observed previously 143.
During initial phase I clinical testing of a CD134 agonist for the treatment of various
advanced cancers, including melanoma, RCC, squamous cell carcinoma (SCC) of the urethra,
prostate cancer, and cholangiocarcinoma, fewer irAEs occurred and an acceptable toxicity
profile was observed 141. 12 out of 30 patients had regression of at least one tumor nodule, and in
an additional 6 patients there were no changes in target lesion measurements (Table 1.1);
however none of the patients demonstrated responses according to RECIST criteria, which
mandate tumor shrinkage of at least 30% to be considered positive clinical responses 141.
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Differences in adverse events seen with anti-CD134 versus anti-CD137 may in part be attributed
to the more widespread expression pattern of CD137 that encompasses not only activated T cells
and Tregs but also several innate cell types such as natural killer (NK) cells and DCs 174-176, in
contrast to CD134, whose expression appears to be more restricted to T cell subsets.
Management of irAEs should be guided by the severity of symptoms and typically
involves early detection, temporary cessation of therapy, careful monitoring, supportive care
such as oral hydration, and tailored symptomatic relief. For more severe irAEs,
immunosuppressive drugs such as corticosteroids are often successful in mitigating symptoms,
and infliximab (which neutralizes TNF-) can be helpful in managing cytokine release
syndrome. Additionally, there are clinical algorithms to aid in determining the appropriate
strategy to best manage irAEs 107,155,177,178. As mentioned previously, symptomatic relief using
these agents has been shown not to negatively impact treatment efficacy, which substantially
enhances the clinical utility of immunomodulatory mAbs.

6. Mechanistic contributions of Fc-FcR interactions
An understanding of the structural features of immunomodulatory mAbs illuminates their
efficacy and adverse event profiles. Such mAbs generally are IgG isotypes and thus share a
common structure composed of two identical, variable fragment antigen-binding (Fab) domains
that confer target specificity, as well as a single, non-variable Fc domain corresponding to the
particular IgG subtype (1-4 in human; 1, 2a, 2b and 3 in mouse). The Fc domain can bind FcRs
on the surface of innate immune effector cells (macrophages, DCs, NK cells, etc.) and B cells.
Depending on cell type and environmental context, Fc binding to surface FcR will engage
signaling pathways in the FcR-bearing cell and help shape functional responses. For example,
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interaction of macrophage FcR with the Fc domains present on an IgG-coated cell can induce
that macrophage to initiate effector functions such as antibody-dependent cell-mediated
cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) 6-9,179. Fc-FcR
interaction thus serves as a homing signal to direct immune effector mechanisms to a specific
target, effectively bridging adaptive (e.g., B cell-generated IgG) and innate (e.g., phagocytosis)
immunity and enabling a number of important biological activities 180.
The canonical FcRs belong to the Ig superfamily and can either transmit an activating
signal (FcRI, IIA, IIC, IIIA and IIIB in human; FcRI, III and IV in mouse) or alternatively an
inhibitory signal (FcRIIB in both human and mouse). The different IgG subtypes possess
variable affinities for specific FcRs and thus differ in the balance of activating versus inhibitory
signals they transmit into FcR-expressing cells 9. Table 1.3 provides a summary of IgG-FcR
interactions relevant to immunomodulatory mAb-based therapy. Due to the fact that human
FcRIIC (expressed in only 20% of patients) and FcRIIIB (a GPI-linked receptor mainly
restricted to neutrophils) have not been well characterized 181, they have been left out of Table
1.3 and will not be considered further. Similarly, human IgG3, which is not used therapeutically
due to relative instability and immunogenicity 181, and mouse IgG3, which does not interact
appreciably with FcRs 181,182, are also excluded from Table 1.3 and from further discussion.
FcRs can be either activating or inhibitory, as determined mainly by their intracellular
signaling components. Activating receptors contain intracellular immunoreceptor tyrosine-based
activation motifs (ITAMs) which transduce stimulatory signals to the receptor-bearing cell when
the extracellular portion of the receptor is ligated. Conversely, inhibitory receptors contain
immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which transduce suppressive signals
when bound by ligand 179 (Table 1.3). The opposing nature of the activating and inhibitory
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FcRs allows for fine-tuning of FcR-mediated immune responses based on the summation of
stimulatory and suppressive inputs 183 (see Figure 1.1). The immune-regulating activities
mediated by FcRs have been reviewed elsewhere 179.
Recently, it was found that inhibitory ITAM (ITAMi) signaling, in the context of lowvalency receptor binding 184, such as that occurring with unbound, soluble IgG (Figure 1.1F),
represents another source of FcR-mediated inputs 185. ITAMi signaling after FcRI (an activating
receptor) binding by immune complexes has been shown, for example, to attenuate IFN-
signaling and induce the secretion of immunosuppressive IL-10 170. The size of immune
complexes seems to be an important factor in determining whether FcR signaling generates a
pro- or anti-inflammatory response 169, with larger complexes generally triggering proinflammatory cytokine activity (Figure 1.1E) and smaller immune complexes (and soluble,
monomeric IgG) appearing to promote anti-inflammatory conditions (Figure 1.1F) . This
phenomenon likely accounts for the clinical benefits of IVIG therapy in treating patients with
rheumatoid arthritis 186, idiopathic thrombocytopenic purpura (ITP) 187, and other autoimmune
disorders 188,189. Our understanding of Fc-FcR interactions and their involvements in numerous
biological processes, however, is far from complete, and their complexities are only now
beginning to be unraveled. Overviews of Fc-FcR interactions and their role in mAb-based cancer
therapy (specifically, their contributions to treatment efficacy) are available 8,9,181,190-192.
The role of FcR-mediated interactions in the function of cytotoxic mAbs such as
rituximab arises predictably from the involvement of innate effector cells in their mechanisms of
cellular elimination 193-196, but defies straightforward prediction in the case of
immunomodulatory mAbs. Since checkpoint inhibitors disrupt inhibitory ligand-receptor
interactions, the involvement of FcR would not seem necessary, for instance, to prevent CTLA-4
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from disrupting B7.1/B7.2 interaction with CD28 during T cell priming in draining lymph nodes.
However, the potency of ipilimumab was found to depend on intratumoral depletion of Tregs 197
due to their constitutive expression of the CTLA-4. Depletion was shown to depend on activating
FcRIV, suggesting macrophage-mediated ADCC as the driving mechanism 78,198,199 (Table 1.4).
The story is further complicated by the fact that ADCC may not be the only mechanism
of Treg depletion. There is evidence that Tregs possess a degree of plasticity and under certain
circumstances can undergo a phenotypic conversion, in which they lose their suppressive
properties and gain effector functionality 200. CD134 agonists were shown to inhibit de novo
Treg induction, expansion, and suppressive function 201, in addition to their ability to promote
effector CD4+ and CD8+ T cell proliferation 126,129. Similarly, GITR agonism was shown to
downregulate Treg-specific transcription factors and cytokines (with complete loss of Foxp3
expression) and upregulate T-bet and Eomesodermin (Eomes) 202. More recent evidence suggests
that costimulation with CD134 plus CD137 agonists can induce Tregs to adopt a cytotoxic CD4+
effector phenotype, expressing Eomes, Granzyme B (GzmB), and IFN-, while retaining Foxp3
expression 203. Additionally, CD137 costimulated Foxp3+ Tregs that express Eomes and GzmB
can kill tumor target cells 204. Thus, it appears that immunomodulatory mAb therapy can exploit
Treg plasticity to reverse tumor-mediated immunosuppression and add to the overall effector T
cell response (Table 1.4).
Costimulatory signaling by TNFR family members is initiated under physiological
conditions when they undergo trimerization upon binding their natural ligands; however, mAbs
can only bind a target bivalently (Figure 1.1A). Thus, generally speaking, costimulatory agonists
cannot on their own induce costimulation. Nevertheless, FcR-mediated, mAb-induced clustering
of receptors facilitates the formation of higher order signaling complexes capable of initiating
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costimulation (Figure 1.1B) and appears to be required for the efficacy of at least some agonists.
Since engagement of activating FcR on DCs enhances their antigen presentation and
costimulatory capacity 205,206, one might predict that activating FcR would be the most potent in
facilitating therapeutic effects of costimulatory agonists. To the contrary, activity of the
proapoptotic receptor agonists (PARA) targeting death receptor (DR) 4, DR5, and CD95 (Fas)
was found to depend on either activating or inhibitory FcR, and in some contexts, inhibitory
FcRIIB was shown to be sufficient in mediating this activity 207. Similar FcR requirements were
later demonstrated for anti-CD40 207-209, thus extending the finding to non-apoptosis-inducing
costimulatory TNFR agonists (Table 1.4). These observations suggested a mechanism whereby
FcRIIB engagement on nearby FcR-expressing cells by TNFR-bound agonist mAbs induces
clustering of TNFRs, thus enabling sufficient induction of costimulatory signaling (Figure 1.1
B). This proposed model was further supported by the discovery that efficacy did not depend on
FcR-dependent signaling in the accessory cell that expresses it 210. Thus, FcR appears to facilitate
agonist-induced costimulation through receptor clustering.
White and colleagues showed that CD40, CD28, and CD137 agonists containing a
subdomain from the Fc hinge region of the B isoform of human IgG2 can function independently
of Fc-FcR interactions, retaining biological effects even after enzymatic removal of antibody Fc
domains 211. The authors proposed that the constrained disulfide hinge configuration facilitates
uniquely compact divalent receptor clustering and thereby the induction of costimulatory
signaling. On the other hand, activating FcR are required to enable other TNFR agonists, such as
GITR 199, CD27 212 and CD134 213, to deplete intratumoral Tregs (as with anti-CTLA-4 mAbs
78,198,199

), implicating innate effector mechanisms (reviewed in 190 and shown in Table 1.4).

Whether activating or inhibitory FcR are involved in the mechanism(s) underlying

23

immunomodulatory agonist-induced boosting of initial antigen-priming in lymphoid organs,
however, remains to be determined in vivo. Interestingly, the therapeutic activity of CD137
agonist in a mouse lymphoma model was actually enhanced in the absence of activating FcRIII
214

. This is a surprising finding, particularly in light of earlier work demonstrating FcR-

dependent CD137 induction on NK cells 215, whose tumoricidal function is well known to be
engaged by CD137 agonist 174. As such, the outcome of FcR-mediated events occurring
following administration of CD137 agonist can vary in a context-dependent manner.
More recently, Dahan et. al., described the Fc-FcR interactions involved in the targeting
of the PD-1/PD-L1 axis using a variety of antagonist mAbs 216. This study revealed that
antagonistic anti-PD-1 mAbs mediate biological activity in a manner that is not dependent on
FcR interaction. As with anti-CD137 agonist 214, engagement of activating FcR leads to a
decrease in efficacy (Table 1.4). This inhibition seems to be mediated by FcR-induced ADCC
directed toward T cells expressing PD-1, depleting the cells intended to be activated. An
additional proposed mechanism of FcR-related diminution of efficacy implicates FcRIIBinduced clustering and consequent stimulation (as with TNFR agonists), in essence converting
the intended blockade of PD-1 into agonistic PD-1 stimulation 216.
The same study uncovered entirely different FcR-dependent mechanisms at work in
mAbs targeting PD-L1, which require the presence of activating FcR-expressing cells for
optimal efficacy. These findings suggest that ADCC-mediated depletion of PD-L1-expressing
myeloid cells within the TME is important for the efficacy of PD-L1-targeted
immunomodulatory therapy (Table 1.4). Furthermore, this mechanism likely synergizes with the
FcR-independent disruption of PD-1/PD-L signaling facilitated by the antagonistic mAbs 106,110.
These data are in agreement with previous work showing that immunosuppressive myeloid cell
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subsets, such as MDSCs 57, can foster a pro-cancer environment barricading the tumor from
immune intervention.
The complexities of Fc-FcR interactions and the roles they play in mediating the activity
of immunomodulatory antibodies is an area of active investigation and has been reviewed
extensively elsewhere 169,179,183,217. Additionally, Offringa and Glennie provide in a Cancer Cell
preview 218 to Dahan et. al.’s report 216 a concise overview of Fc-FcR roles in
immunomodulatory therapy that includes those just uncovered for anti-PD-1 and anti-PD-L1
antagonists.

7. Expert opinion: Is it possible to selectively increase safety while maintaining
efficacy?
Modulation of the immune system with checkpoint inhibitors and costimulatory agonists has
emerged as a highly promising approach to cancer therapy. Improved durability and rates of
response, more tolerable side effect profiles and extensive clinical applicability (in both solid and
liquid tumors) set immunomodulatory mAbs apart from previous generations of cancer
therapeutics. A growing body of evidence supports the notion that immunomodulatory agents
will soon become standard first-line therapies. Table 1.1 summarizes the current development
status for representative mAbs and lists for each phase of clinical testing specific
conditions/indications in which they are being evaluated. Data on PFS, OS, and best overall
response (BOR) rates are essential to evaluate different treatments. Additionally, although rates
of grades 3/4 side effects are included in clinical trials and can be used as an indirect measure of
quality of life (QOL), direct assessment will be of great value moving forward.
Evidence has shown that the efficacy and adverse event profile of a given agent can vary
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significantly from patient to patient. The identification of biomarkers to predict patient likelihood
of response and the potential of treatment toxicity is essential to the design of patient-specific
treatment strategies, as well as to the proper clinical testing of these agents. Importantly, cancer
patients must be screened to assess their eligibility, since inclusion in clinical trials of patients
unable to respond can dilute overall efficacy determined by the study and potentially mask the
true clinical potency of new agents being developed 157. One potential biomarker identified for
ipilimumab response is the cancer/testis antigen NY-ESO-1, which is expressed normally in the
testis and placenta, as well as aberrantly in a subset of advanced melanomas. It was found that
NY-ESO-1 seropositivity, and to greater extent the existence of NY-ESO-1 specific CD8+ T cells
in the periphery, correlates positively with clinical responsiveness to ipilimumab 219. It was also
found that patients with lactate dehydrogenase levels exceeding twice the upper limit of normal
were far less likely to benefit from ipilimumab therapy in the long-term 220. Moreover, recent
evidence has demonstrated potential value in using PD-L1 expression as a biomarker to
determine the likelihood of patient response to PD-1 antagonism and the likelihood of enhanced
clinical benefit from supplementing anti-PD-1 with additional therapeutics in combination 106,110
(Table 1.2). Updated results from clinical trials, however, demonstrated that PD-L1 expression
may not be a useful marker for predicting patient response. On the other hand, combination
therapies may be beneficial in patients with BRAF mutations (Table 1.2), and several other
potential biomarkers showed some evidence of predictive value 110.
Interestingly, it was recently shown that gut microbiota composition can influence the
efficacy of anti-CTLA-4 therapy. Specifically, the gut microbiota is required for antitumor
responses with the anti-CTLA-4 mAb 9D9 in multiple mouse models of melanoma, sarcoma,
and colon cancer. Data also showed that the microbiota was necessary for mAb-induced
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activation of effector CD4+ T cells in the spleen 221. These findings align with previous
knowledge that Tregs are abundant in the GI tract. The identification of individual bacterial
species associated with anti-CTLA-4 efficacy suggested that their presence and relative
abundance in a patient’s gut microbiota could serve as a biomarker to predict likelihood of
treatment response. Furthermore, feces harvested from ipilimumab-treated patients were found to
differ in microbiota composition, which gradually shifted in favor of the efficacy-enhancing
species. Intriguingly, fecal microbial transplants into tumor-inoculated mice with patient feces
samples containing significant numbers of these microbes helped to generate effective antitumor
responses, whereas transplantation of feces containing fewer of these specific microbes were
unable to respond 221.
There also appears to be a genetic basis for the likelihood of beneficial response to
immunomodulatory therapy. Genetic analysis of 64 ipilimumab-treated melanoma patients
uncovered a correlation between mutational load and clinical benefit and identified a neo-antigen
landscape specific to tumors that are highly responsive to treatment 222. Some specific genetic
mutations 223 and the presence of particular single-nucleotide polymorphisms 224 have also been
shown to predict clinical response. Interestingly, the single-nucleotide polymorphisms (SNPs)
that correlated with beneficial clinical response did not show any correlation with the occurrence
or severity of adverse events 224, suggesting that the mechanisms underlying efficacy and toxicity
do not overlap entirely and can thus be differentially targeted when designing future
immunomodulatory mAbs for greater therapeutic index. This study also supports an earlier
hypothesis that some mutations considered silent passengers should instead be classified as
immune determinants 225 that collectively define immunogenicity and susceptibility to antitumor
effector mechanisms employed by the immune system. Accordingly, genetic screening could be
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employed to identify likely responders to therapy and help ensure that patients are offered only
those treatments from which they are likely to benefit.
The process of selecting new immunomodulatory antibodies for clinical development
also needs to be improved at the preclinical level in order to better predict their effects in
humans. The use of in vitro screening assays is convenient, but results obtained must be
interpreted with caution, because numerous factors such as cell culture density,
microenvironment architecture, and stimulation timeframes often differ substantially from those
in real patients 226. The unanticipated consequences of the TGN1412 trial, for example, was later
determined to result from failure to take into consideration differences in CD28 expression
patterns between humans and cynomolgus macaques 227,228. This unfortunate event has helped
lead to the development of new screening techniques and safety measures, which are already
being utilized in designing and testing new therapies 228. Prevention of such incidents will be
essential to continued progress in this field.
The difference in response kinetics when comparing immunomodulatory mAbs to
traditional cancer therapeutics is also important to consider in future clinical testing protocols.
Immunomodulatory antibodies, which function indirectly via immune system activation, can take
longer to mount an attack and thus warrant adjustment to currently defined endpoints and other
measures used to evaluate agents 229. The importance of this last point is illustrated in the
premature halting of a phase III trial with the anti-CTLA-4 agent tremelimumab due to apparent
lack of improvement in survival. However, follow-up investigation of study participants
eventually revealed improvements occurring after 2 years 230, reflective of the delayed evidence
of therapeutic response seen with these agents. Similarly, as discussed earlier, the absence of
efficacy reported for an anti-OX40 agonist antibody despite initially promising data
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demonstrates the incompatibility of traditional RECIST criteria with immunomodulatory
therapies 141. In fact, even with successful therapeutic outcomes tumor shrinkage would not be
expected to occur for some time after treatment is initiated. This is because tumoricidal
responses induced by immunomodulatory mAbs rely on effector cell infiltration into the TME;
thus, upon measurement, any tumor shrinkage would likely be difficult to detect due to
lymphocytic influx localized to tumor sites. Therefore, appropriate additional criteria, such as
immune cell phenotypes, frequencies, and overall abundances, both in circulation and within
TMEs, need to be incorporated for improved evaluation of clinical trials 231. Only then can we be
confident that we are accurately characterizing future generations of immunomodulatory
therapeutic candidates.
As mentioned earlier, the ability to selectively enhance efficacy and/or limit toxicity
likely depends on the specific mechanism(s) responsible for each. There is considerable overlap
in the immune effector mechanisms involved in beneficial therapeutic antitumor effects and
harmful adverse events. For instance, TNF- has potent tumoricidal activity, but can be a
causative factor in cachexia, insulin resistance and cytokine release syndrome 232-235. Further,
initial clinical trials testing ipilimumab found a positive correlation between therapeutic
responses and the prevalence and severity of adverse events 178,236,237, raising the critical question
as to what extent adverse events can be limited without compromising therapeutic efficacy.
Fortunately, extensive clinical testing of ipilimumab has provided encouraging results in this
regard, specifically that ipilimumab-responsive patients who develop irAEs can continue to
benefit from an anti-tumor response even after pharmacologic reversal of associated symptoms
with, for example, administration of corticosteroids 106,110,177. Reversal of irAEs and cytokine
release syndrome without loss of efficacy was also achieved in other T cell-mediated cancer
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therapies, in which inhibition of TNF- with etanercept 238 and inhibition of IL-6 signaling with
tocilizumab 238,239 were effective. Alternative agents that might be useful in managing cytokine
release syndrome during immunotherapy include inhibitors to MCP-1, MIP-1, IL-2R, and IL1R 240 (depicted in Figure 1.1).
Combinations of immunotherapies 109, as well as immunotherapies used in conjunction
with traditional treatment options such as chemotherapy 241 and radiotherapy 242 have been
attempted in search of treatment approaches with enhanced efficacy and improved safety
profiles. Combination therapy has opened the possibility of limiting the occurrence of irAEs due
to additive (and for certain combinations perhaps even synergistic) effects of multiple agents,
which could allow for administration of lower doses. Although the frequency and severity of
adverse events have been greater with combinations than with individual monotherapies thus far
106,110

(Table 1.2), the ability to titrate dosages could potentially avoid many adverse events

directly. A detailed mechanistic understanding of how these therapeutics elicit their associated
beneficial and toxic effects is crucial to designing strategies that selectively block the latter.
Ideally, these approaches will facilitate an overall advantage in favor of enhanced efficacy over
adverse events. Ultimately, the benefits and risks of specific combinations will need to be
addressed in future trials. Melero and colleagues recently published a comprehensive review
summarizing general concepts, specific examples under development, and important
considerations in the design of combination immunotherapies 243.
It seems likely that Fc-FcR interactions also play a role in mediating at least some of the
adverse events elicited by immunomodulatory mAbs. For instance, target expression on
therapeutically-irrelevant cell types could potentially lead to collateral damage of these cells via
ADCC or ADCP (Figure 1.1D). Thus, while ADCC/ADCP might be therapeutically beneficial
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by depleting intratumoral Tregs with mAbs to CTLA-4, GITR and OX40 78,198,199,213 (Table 1.4),
it might be problematic, for instance, with anti-CD137, since CD137 is expressed on a variety of
cell types, some of which appear not to be involved in the antitumor response 244. Neurons,
astrocytes and microglia 245, for example, are among these therapeutically-irrelevant, CD137expressing cell types. Additionally, endothelia can express CD137 in response to inflammatory
mediators 246 and in diseases such as atherosclerosis 247.
Furthermore, expression of soluble forms of some targets (e.g., CD134 and CD137) has
been found in a variety of pathological conditions 248-250, raising the potential for the formation of
immune complexes which can trigger inflammation (Figure 1.1E) 169 and may potentially be
involved in mechanisms driving pathological immune hyper-reactivity, such as that occurring in
IgG-mediated anaphylaxis 251. Finally, surface coating of IgG on either therapeutically-relevant
or -irrelevant cells could cause innate cells expressing activating FcR to release proinflammatory cytokines contributing to adverse events 169,252. In sum, although Fc-FcR
interactions may be necessary for the full therapeutic efficacy of immunomodulatory mAbs, they
might also be responsible for therapeutically-complicating adverse events through a variety of
potential mechanisms. Further, these adverse events might be exacerbated by other pathologies
(e.g., underlying infection or autoimmune predisposition) from which cancer patients might be
suffering. Nevertheless, seemingly contradictory evidence showing both pro- and antiinflammatory cytokine secretion in response to FcR engagement illustrates our incomplete
understanding of FcR-mediated immune functions.
Despite these gaps in understanding, Fc-FcR interactions are likely responsible for at
least some of the toxicities seen with immunomodulatory mAb therapy. In such cases, preventing
these interactions may help limit adverse events to increase therapeutic index and enhance
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precision medicine. This notion is additionally supported by the heterogeneity of responses to
FcR-dependent mAb activity. For instance, the absence of a human homolog to the high-avidity
FcRIIB-binding of mouse IgG1 may limit efficacy of some costimulatory agonists (Table 1.3).
Furthermore, patient response heterogeneity can arise from relative levels of FcR expression and
functional status, which can vary widely between tissues and cell types. For example, although
most innate cells express both activating and inhibitory FcRs, NK cells are known to express
only activating receptors in mice and humans (except for a recently discovered subset of NK
cells expressing FcRIIB), whereas B cells only express inhibitory receptor 179. The different
distributions of such cells likely explains the tissue- and organ-specific differences in overall
response to therapy 12. Interestingly, it was recently suggested that in a murine model peritoneal
and visceral adiposity can influence the magnitude of cytokine-mediated toxicity associated with
the presence of resident M1-polarized macrophages 171. Other factors include current immune
status (e.g., active responses to infection), and patient-specific differences in both FcR-mediated
signaling summation patterns (i.e., activating vs. inhibitory FcR inputs) and FcR-specific
avidities to various IgG isotypes (Table 1.3). Additionally, the existence of allotypic variants
with different binding affinities contributes to patient response heterogeneity; so far, human
FcRIIa and FcRIIIa each have had two variants characterized 253.
Establishing FcR-independent mechanisms of immunomodulatory mAb activity is
therefore a highly desirable goal. Antibody multimerization has been shown to be an effective
strategy to bypass FcR requirements, enabling the preservation of anti-CD40 agonist activity in
vitro and in vivo, as well as in a model of lymphoma with mice completely lacking all FcRs 254
(Table 1.4). Immunomodulatory therapy can also be optimized using mAb engineering to alter
FcR binding properties. Early studies focused on increasing binding avidity of IgG to activating
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FcR, which could be accomplished using protein engineering 255,256, as well as modification to
antibody glycosylation 257,258. Additionally, selective enhancement of FcRIIB binding was used
to generate an anti-CD137 agonist with increased agonistic activity in vitro 259. Individual FcRs
have also been shown to exhibit differential contributions to cellular functions; for example, it
has been demonstrated that FcRI was largely responsible for secretion of both antiinflammatory IL-10 260 and pro-inflammatory cytokines 261. A suggested implication of this
findings was that macrophage-mediated ADCC and ADCP could potentially be uncoupled from
antibody-dependent cytokine release (ADCR), a feat which was accomplished recently by
Kinder et. al., using an Fc-engineering approach to modulate cytokine release while leaving cellkilling activity intact 261. The ability to selectively fine-tune or prevent cytokine release thus
opens the possibility of limiting cytokine-related adverse events without losing effector capacity
and tumoricidal activity. Contrarily, in situations where the secretion of anti-inflammatory
cytokines might be hindering efficacy, selective attenuation of ADCR would be advantageous.
Additionally, the human IgG2 isotype (specifically the B isoform) was shown to possess
the unique ability to exhibit activity in an FcR-independent manner, likely due to an especially
compact geometry and constrained disulfide hinge configuration 211. White and colleagues
posited that these properties enable sufficient clustering of TNFRs to reach a signaling threshold
beyond which stimulation ensues. Notably, this phenomenon was shown for agonists targeting
multiple costimulatory receptors, including CD40, CD28, and CD137, and it was further
demonstrated that selective mutagenesis could generate a wide range of agonistic activities,
without altering receptor binding avidity (Table 1.4). That human IgG2 is capable of exerting
superior agonistic activity in an FcR-independent manner potentially accounts for data from
clinical trials demonstrating superior potency of the anti-CD40 agonist CP-870,893, an IgG2
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isotype (Table 1.1), compared to those of other isotypes 262,263.
A greater understanding of the mechanisms behind immunomodulatory mAb therapy will
be critical for the future optimization of these therapeutic agents. Importantly, the mechanisms
underlying efficacy and adverse events need to be further delineated. Recent characterization of
PD-1/PD-L1-targeted therapies 216 further adds to the ever-expanding complexity of the
mechanisms at work in immunomodulatory therapy, while also illustrating the importance of
proper antibody isotype selection and the value of Fc domain modification in order to optimize
efficacy. Much work is also needed to explain the context-dependent pro- and anti-inflammatory
responses (Figure 1.1E, F) induced by FcR binding to mAb Fc domain. While many data
support the idea that avoiding FcR activity will help limit adverse events, the anti-inflammatory
responses to FcR signaling in certain contexts now pose the possibility that FcR engagement
actually contributes negatively to therapeutic efficacy, and that circumvention of FcR interaction
could lead to an enhancement of activity (perhaps even concurrently with attenuation of adverse
events). Conversely, it is possible that FcR-mediated pro-inflammatory cytokine secretion
contributes to overall antitumor efficacy, representing a benefit that would be lost if FcR
engagement were avoided. Only with continued investigation will we be able to accurately
predict how adjustments to Fc-FcR interactions will impact efficacy and toxicity. Therapeutic
approaches that do not engage FcR yet retain the ability to effectively stimulate their target
pathways, will potentially be capable of inducing beneficial therapeutic responses in cancer
patients while sparing them from having to endure the dangerous adverse events of today’s
therapies. Hence, perhaps we can have our cake and eat it too.

8. Tables and Figures
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Table 1.1: Clinical results for representative immunomodulatory mAbs used to treat cancer
Checkpoint Inhibitors
PD-1
Nivolumab
IgG4

Target
Agent*
Isotype

CTLA-4
Ipilimumab
IgG1

Company

Bristol-Myers Squibb

Bristol-Myers Squibb

Approved/Marketed

Costimulatory Agonists
CD134 (OX40)
CD137 (4-1BB)
MEDI6469****
Urelumab
murine IgG1
IgG4
MedImmune/
Bristol-Myers
Pfizer/Roche
AstraZeneca
Squibb

PD-L1
Atezolizumab
IgG1
Genentech/
Roche

CD40
CP-870,893**
IgG2

Approved/Marketed

Phase III

Phase I

Phase I/II

Phase II

Malignant melanoma

Malignant melanoma,
NSCLC, RCC

-

-

-

-

Phase III
Indications

Glioblastoma,
NSCLC, RCC, SCLC,
prostate

Glioblastoma, gastric,
HNC, SCLC

Bladder,
breast,
NSCLC, RCC

-

-

-

Phase II
Indications

Gastric, MDS,
esophageal, ovarian,
UGC, lymphoma,
brain metastases

CRC, solid
tumors, soft
tissue sarcoma

-

-

CLL, malignant
melanoma

Phase I/II
Indications

Solid tumors

DLBCL,
follicular
lymphoma

-

Breast, DLBCL,
prostate cancer,
solid tumors

NHL, solid
tumors

Malignant
melanoma,
MM, MDS,
hematological
malignancies

PDA, solid
tumors

CRC, HNC

MM, CRC, HNC

ORR 20% (6
PR), phase I,
with
chemotherapy,
solid tumors 139

No PR, but
tumor shrinkage
in 40% (12 of
30) following
single dose;
induction of
HAMA
prevented
additional doses
being given
141***

ORR 5.6% (3 of
54), phase I,
melanoma;
phase II study
terminated due
to
hepatotoxicity;
newer trials
using lower
dosages 142

Fatigue (81%)
most common;
does-limiting
grade 3 CRS,
grade 4 TIA 139

Well-tolerated,
brief grade 3
lymphopenia,
fatigue, fevers,
chills, mild rash
observed 141***

Cytopenias and
liver
inflammation
(elevated
ALT/AST), dose
dependent;
fatigue, rash,
fever 142

Highest
Phase of
Testing
Marketed/
registered
Indications

Phase I
Indications

Efficacy

-

ORR 10.9%, phase III,
stage III/IV melanoma
vs 1.5% gp100 alone
OS=10.1 months
vs 6.4 (gp100 alone) 80
ORR 19.0%, phase III,
stage III/IV melanoma

AML, CLL, breast,
DLBCL, MDS, UGC,
esophageal, ovarian,
follicular and
Hodgkin’s lymphomas
CRC, HCC, NHL,
solid tumors,
hematological
malignancies

CML, hepatitis C

ORR 40.0%, phase III,
stage III/IV
melanoma, vs 13.9%
for dacarbazine 103
ORR 43.7%, phase III,
stage III/IV melanoma
106

ORR 38%,
phase II,
advanced
NSCLC, PDL1+; compared
to 13% for
docetaxel 264

106

Adverse
Events

Toxicities generally
immune-related; rash,
colitis, diarrhea,
hepatotoxicity,
endocrinopathies,
neuropathies 80,106,265

Generally, more
tolerable than
ipilimumab; fatigue,
rash, diarrhea, pruritis,
pneumonitis, fever can
occur 100,101,106

Toxicities
similar to those
seen with antiPD-1; grades
3/4 adverse
events have
been
uncommon 264

Information on clinical trials obtained from ClinicalTrials.gov.
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*Particular agents listed here are only representative; there are a number of other agents to
the same and/or other targets in various stages of development.
**Pfizer’s CP-870,893 is now licensed to Roche and has been renamed RO7009789; ongoing
clinical trials are listed under RO7009789.
***Efficacy and adverse events based on phase I testing of a different OX40 agonist, 9B12.
****MedImmune/AstraZeneca has recently begun recruiting for a phase I trial with a
humanized anti-CD134 agonist (MEDI0562) in adults with selected advanced solid tumors
(NCT02318394).
NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma; SCLC, small cell lung
carcinoma; MDS, myelodysplastic syndromes; UGC, urogenital carcinoma; HNC, head and
neck cancers; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL,
diffuse large B cell lymphoma; NHL, non-Hodgkin’s lymphoma; CML, chronic myeloid
leukemia; CRC, colorectal cancer; MM, multiple myeloma; PDA, pancreatic ductal
adenocarcinoma; CRS, cytokine release syndrome; TIA, transient ischemic attack; ORR,
objective response rate; PR, partial response; HAMA, human anti-mouse antibodies.
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Table 1.2: Combination immunotherapy with ipilimumab (anti-CTLA-4) and nivolumab (antiPD-1) in previously-untreated metastatic melanoma

Efficacy

Adverse
events

Treatment*
ORR**
Median PFS (Intention-to-treat)
Median PFS (PD-L1-positive)
Median PFS (PD-L1-negative)
Rate of any adverse event
Severe***

Ipilimumab
19.0%
2.9 months
3.9 months
2.8 months
99%
55.6%

Nivolumab
43.7%
6.9 months
14.0 months
5.3 months
99.4%
43.5%

Both
57.6%
11.5 months
14.0 months
11.2 months
99.7%
68.7%

This table represents an abbreviated version of findings from the randomized, double-blind,
phase 3 study 106 deemed most important
*Number of patients per group (n) ranged from 311-316.
**Response rates determined by the investigator using Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.1.
***Defined as grades 3/4 based on severity determined using the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
ORR, objective response rate; PFS, progression-free survival.

Recently reported 3-year update 110 on results from the clinical trial referenced above:

Efficacy

Adverse
events

Treatment*
ORR**
3 Year PFS Rate
3 Year OS Rate
3 Year Median PFS
3 Year Median OS
3 Year OS Rate (BRAF mut.)
3 Year OS Rate (BRAF WT)
Rate of treatment-related irAE
Severe***

Ipilimumab
19%
10%
34%
2.9 months
19.9 months
37%
32%
86%
28%

Nivolumab
44%
32%
52%
6.9 months
37.6 months
56%
50%
86%
21%

Both
58%
39%
58%
11.5 months
38.2 months#
68%
53%
96%
59%

*Number of patients per group (n) ranged from 311-316.
**Response rates determined by the investigator using Response Evaluation Criteria in Solid
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Tumors (RECIST), version 1.1.
***Defined as grades 3/4 based on severity determined using the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
# Median PFS not yet reached.
ORR, objective response rate; PFS, progression-free survival; OS, overall survival.
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Table 1.3: FcR properties, expression patterns and IgG isotype binding affinities in mice and
humans
Species
Receptor

Mouse

Function

FcRI
Activating

FcRIII
Activating

FcRIV
Activating

FcRIIB
Inhibitory

Signaling

ITAM

ITAM

ITAM

ITIM

Allotype

n/a

n/a

n/a

n/a

IgG1

-

++

-

+++

IgG2a

++++

++

+++

++

IgG2b

++++

++

++

DC

DC
Mac
PMN
NK

DC
Mac
PMN
NK

+++
B
DC
Mac
PMN
NK
T***

Expression
patterns**

Species
Receptor

Human

Function

FcRI
Activating

FcRIIa
Activating

FcRIIIa
Activating

FcRIIB
Inhibitory

ITAM

ITIM

Signaling

ITAM

Allotype*

n/a

H131

ITAM
R131

F158

V158

n/a

IgG1

++++

+++

+++

++

+++

++

IgG2

-

++

+

-

+

-

IgG4

++++

++

++

++

++

Expression
patterns**

DC
Mac
PMN

++
B
DC
Mac
PMN
NK****

DC
Mac
PMN

Mac
PMN
NK

*Only human allotypes that have been sufficiently characterized are included. For each
receptor, the more common variant appears first.
**Low expression levels indicated by italics.
***Expressed by mouse memory CD8+ T cells.
****Expressed by a subset of human NK cells.
ITAM, immunoreceptor tyrosine-based activation motifs; ITIM, immunoreceptor tyrosinebased inhibitory motifs; B, B cell; DC, dendritic cell; Mac, macrophage/monocyte; PMN,
polymorphonuclear cell (neutrophil); NK, NK cell; T, T cell.
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Table 1.4: Characterizing potential Fc-FcR interactions required for efficacy and/or adverse
events of representative immunomodulatory targets
FcR Requirements for
Biological Functions

FcRIndependent

mAb
Target

Block ligand
binding

Counterregulatory
signaling*

Activate
Costim

CTLA-4

Yes

Yes

-

Yes

-

-

PD-1

Yes

Yes

-

-

-

-

PD-L1

Yes

-

-

-

Yes

Yes**

CD40

-

-

Yes

-

-

Yes**

CD134
(OX40)

-

-

Yes

Yes

-

-

CD137
(4-1BB)

-

-

Yes

Yes

-

-

GITR

-

-

Yes

Yes

-

-

DR5

-

-

-

-

-

Yes

CD95
(Fas)

-

-

-

-

-

Yes

mAb Class

Checkpoint
Inhibitors

Costim
Agonists

PARA

FcRDependent
Deplete/
Deplete/Alter
Alter Treg Myeloid Cells
in TME
in TME

Tumor
Depletion/
Apoptosis

Additional
comments

FcR engagement
diminishes efficacy

FcRIIBdependent***
Treg depletion due
to ADCC and/or
phenotypic
conversion
FcRIII diminishes
efficacy; FcRIIBdependent***
Treg depletion due
to ADCC and/or
phenotypic
conversion
FcRIIBdependent****
FcRIIBdependent****

Mechanisms that occur only during particular circumstances are italicized.
*Possibly FcR-independent; not yet characterized.
**Some tumors cells can express surface this target.
***Can be activating FcR-dependent and/or FcR-independent in certain contexts.
****Can be activating FcR-dependent in specific circumstances.
Fc, fragment crystallizable; FcR, Fc receptor; mAb, monoclonal antibody; Treg, regulatory
T cell; TME, tumor microenvironment; ADCC, antibody-dependent cell-mediated
cytotoxicity; PARA, pro-apoptotic receptor agonists.
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Figure 1.1: Role of Fc-FcR interactions in mediating therapeutic efficacy and adverse events
of antibody-based immunomodulatory therapy (using anti-CD137 agonist as an example)
Monoclonal antibodies (mAbs) bind costimulatory tumor necrosis factor receptor (TNFR)
superfamily members bivalently, which is insufficient to initiate costimulatory signaling in the T
cell (A) unless fragment crystallizable receptor (FcR) is present on nearby innate accessory cells
to facilitate costimulatory receptor clustering (B). Clustering of activating FcR can also signal to
the FcR-bearing accessory cell (C), leading to the release of pro-inflammatory cytokines (TNF-

41

, IL-1, IL-6, etc.), which can potentially contribute to cytokine release syndrome. Conversely,
cytotoxic or phagocytic innate cells expressing activating FcR can kill therapeutically-irrelevant
cells expressing the mAb target via antibody-dependent cell-mediated cytotoxicity (ADCC) or
antibody-dependent cellular phagocytosis (ADCP), respectively (D). It might also be directed
against the T cells undergoing costimulation (not shown), which could account for recent
findings that activating FcR engagement can negatively impact efficacy in certain scenarios. The
precise nature of FcR-triggered responses by accessory cells depends ultimately on a variety of
factors, such as the relative ratio of activating to inhibitory FcRs engaged (not depicted here), as
well as the structural/geometric context of FcR ligation; for example, large immune complexes
comprised of IgG-coated soluble antigens have been shown to increase inflammatory cytokine
production (E), whereas interaction with soluble, unbound IgG (i.e., under homeostatic
conditions) or small immune complexes appears to suppress hyper-activation of immune cells by
inducing the secretion of anti-inflammatory cytokines, such as IL-10, or by suppressing the
secretion or signaling of inflammatory cytokine secretion (F). Although pro-inflammatory
cytokines play a causative role in therapy-associated adverse events, their effects could also
contribute to overall antitumor efficacy. This last point is an important consideration, since
disruption of Fc-FcR interactions could impact both adverse events and efficacy, depending on
the particular context. Worth noting is that avoiding FcR-induced inflammatory responses would
not completely prevent therapy-associated adverse events, which is thought to be mediated in
part through the activation of specific effector T cells themselves.
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Chapter 2. Materials and Methods

1. OrthomAb synthesis
The heterobifunctional chemical linkers trans-cyclooctene-PEG4-NHS ester (TCO) and
methyltetrazine-PEG5-NHS ester (MTz) (Figure 2.1, both from KeraFast) were coupled to the
mAbs anti-CD137 (clone 3H3, rat IgG2a) and -CD134 (clone OX86, rat IgG1) (10 mg each, both
from BioXCell) in 4 ml PBS at a linker:mAb molar ratio of 7:1 at room temperature for 1 hour.
Coupled mAbs were desalted using Amicon Ultra-4 Centrifugal Filter Units with Ultracel-10
membranes, concentrated to a volume of 1 ml each, and then clicked together by mixing
followed by 1-hour incubation at room temperature. The resulting heteroconjugate (OrthomAb)
was then isolated from the heterogeneous mixture of reaction products (that also included
unlinked monomers and higher-order multimers) using a BioLogic DuoFlow QuadTec 10
medium-pressure liquid chromatography system (BioRad) to perform 3 successive rounds of
size-exclusion chromatography with a HiPrep 16/60 Sephacryl S-300 HR column (GE
Healthcare Life Sciences). Chromatographic tracings of A280 versus time and SDS-PAGE were
used to visualize species present in each fraction, and appropriate fractions were pooled for
subsequent purifications. Purity of the final isolated OrthomAb heterodimer was determined
using ImageJ densitometry software (NIH), and concentration was determined by Pierce BCA
Protein Assay (Thermo Fisher Scientific). An isotype control heteroconjugate was generated
using similar methodology and anti-HRP (clone HRPN, IgG1) and anti-TNP (clone 2A3, rat
IgG2a) (both from BioXCell).
Figure 3.2 is an illustrated outline of OrthomAb synthesis.
Figure 3.3 shows how click reaction parameters were optimized to improve yield and purity.
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Anti-CD134 and anti-CD137 homodimers were also synthesized using a similar protocol. These
are depicted in Figure 4.5, but not used in experiments included in this work.
Fc-less OrthomAb was also generated using a similar protocol, except that each antibody was
digested with pepsin prior to click coupling. Refer to Figure 5.2 for more details.

Figure 2.1: Chemical structures of the click chemicals MTz (top) and TCO (bottom)

2. Mice
6- to 8- week old male or female C57BL/6 (WT) mice (purchased from the Jackson Laboratory)
or H2Kb-restricted, ovalbumin (OVA) epitope (257SIINFEKL264) TCR-transgenic (Tg) Rag1-/mice on the C57BL/6 background (OT-I RagKO mice, bred and maintained in-house) were used
as sources of splenocytes for in vitro cultures. 6- to 8- week old female WT mice were used for
B16-F10 tumor therapy experiments, that were performed as previously described 266. Additional
mouse strains that were bred for and used in the experiments outlined in Chapters 4 and 5
include the following:
•

CD134-/- mice on C57BL/6 background and on OT-I Rag-/- background

•

CD137-/- mice on C57BL/6 background and on OT-I Rag-/- background

•

CD134-/-CD137-/- (DKO) mice on C57BL/6 background and on OT-I Rag-/- background
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Pups from TCR transgenic (Tg) breeder cages were phenotyped by performing FACS analysis
on blood samples (1-2 drops) that were collected by nicking the tip of the tail. Pups from some of
the other transgenic and knockout breeder cages were genotyped by PCR analysis of genomic
DNA samples prepared from small (0.5 cm) tail biopsies. B16 tumor cells in 100-200 l HANKS
were injected intradermally. Procedures involving mice were conducted in a manner to ensure
that discomfort, distress, pain and injury would be limited to that which is unavoidable.
Procedures including collection of blood and DNA samples from the tail were performed using
sharp scissors that subject the mice to minimal amounts of pain and discomfort. Tumorinoculated mice were euthanized when they develop tumors that reach a size of 200 mm2 or
become necrotic. All mice were maintained in the UConn Health Animal Facility in accordance
with National Institutes of Health and UConn Health Institutional Animal Care and Use
Committee (IACUC) guidelines.

3. In vitro costimulation assays
B6 or OT-I splenocytes (1 x 105 cells in 200 l RPMI plus 10% FBS per well in a 96-well plate)
were stimulated for the indicated times with the indicated amounts of anti-CD3 mAb (clone 1452C11, BD Biosciences) or SIINFEKL peptide (NE BioLabs), respectively, plus OrthomAb,
unlinked costimulators or control polyclonal rat IgG. Secreted cytokines in culture supernatants
were measured using ELISA kits from BD Biosciences (for IFN-, IL-2 and IL-6) and R&D
Systems (for IL-17) as per the manufacturers’ instructions. Cytokine concentrations were
calculated using MARS Data Analysis Software from absorbance values measured using a
CLARIOstar microplate reader (BMG LABTECH). Flow cytometry was used to measure cell
proliferation (dilution of CellTrace Violet, Thermo Fisher Scientific), and induction of CD134
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(OX86), CD137 (1AH2) and CD25 (PC61.5) surface expression on conventional (Foxp3neg)
CD4+ and CD8+ T cells and Foxp3+CD4+ T cells. Ghost Dyes (Tonbo Biosciences) were used to
assess cell viability. Intracellular staining for Foxp3 (FJK-16s), GzmB (NGBZ) and Eomes
(Dan11mag) was performed following fixation and permeabilization using Foxp3 staining buffer
(Tonbo Biosciences). Intracellular cytokine staining was performed after 4-hour restimulation
with PMA + Ionomycin (CALBIOTECH) and GolgiPlug (BD Biosciences). Antibodies were
purchased from BD Biosciences, eBioscience, or Tonbo Biosciences, and data were acquired
using an LSR II (BD Biosciences) or MACSQuant Analyzer 10 (Miltenyi Biotec), and analyzed
using FlowJo software (FlowJo, LLC).

4. Tumor immunotherapy
B16-F10 melanoma cells (1 x 105, American Type Culture Collection) that were passaged less
than 1 month were intradermally injected into the shaved back of 6-8 weeks old female C57BL/6
mice. Costimulation therapy was administered at a dose of 150 g, when tumors first became
visible (day 2 or 3, when tumors were at least 1 mm x 1 mm surface area), and tumor growth
monitored every 1-2 days at the indicated times. Booster dose(s) were administered as indicated.
Surface area (mm2) was calculated by multiplying the longest diameter and the diameter
perpendicular to it, both measured with calipers. Area under the curve (AUC) analysis was
performed previously described 267.

5. Statistics
Graphs were generated and statistical analyses performed using GraphPad Prism (GraphPad
Software, Inc.). Comparisons between two groups were performed using unpaired, two-tailed, t
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tests plus Welch’s correction. Comparisons between three or more groups were performed using
one-way ANOVA plus Tukey’s multiple comparison test. Comparisons between titration curves
or time courses of two groups were performed using two-way ANOVA plus Sidak’s multiple
comparison test. Comparisons between titration curves or time courses of three of more groups
were performed using two-way ANOVA plus Tukey’s multiple comparison test. Quantitative
data are expressed as mean value  SEM or SD for data sets with n≥3 or n=2, respectively.
Tumor survival curve comparisons were performed using the log-rank (Mantel-Cox) test.
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Chapter 3. A Novel Biologic Platform Elicits Profound T Cell Costimulatory Activity and
Antitumor Immunity in Mice

This work was published in Cancer Immunology, Immunotherapy, published online
on January 11th 2018, under the title “A novel biologic platform elicits profound T
cell costimulatory activity and antitumor immunity in mice”, authored by Joseph M.
Ryan, Payal Mittal, Antoine Menoret, Julia Svedova, Jeffrey S. Wasser, Adam J.
Adler, and Anthony T. Vella. Some modifications to the original text were made to
accommodate additional figures and to incorporate it into the overall context of this
dissertation.
Copyright 2018. Cancer Immunology, Immunotherapy 268

1. Introduction
Biologics that target tumor cell surface proteins are effective in treating certain cancers. For
instance, the anti-CD20 mAb (rituximab) elicits ~50% response rates in non-Hodgkin's B cell
lymphoma patients who previously failed chemotherapy 194,269. Nevertheless, relapse can occur
due to outgrowth of resistant tumors 270, and many cancers are not amenable to treatment with
these types of mAbs that target antigens expressed on both tumors and the healthy tissues from
which they arise. Alternatively, immunomodulatory mAbs can target tumors indirectly by
activating antitumor immune responses. Thus, although tumors express mutated proteins that
give rise to neoepitopes that can be recognized by CTL 271,272, they employ a variety of
immunosuppressive mechanisms to evade T cell-mediated elimination 57,273,274. For example, T
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cell function can be dampened through engagement of checkpoint receptors by ligands expressed
on APC 275, tumor cells or tumor-infiltrating myeloid cells 276. So far, mAb antagonists to the
checkpoint molecules CTLA-4 and PD-1/PD-L1 have been approved to treat patients with
melanoma and other advanced cancers 79,80,100,104, and antagonists to other checkpoint molecules
such as LAG-3, VISTA, Tim-3 and TIGIT are under development 277,278. Another mechanism
that contributes to ineffectual antitumor T cell responses is presentation of tumor epitopes by
APC expressing low levels of costimulatory ligands 116,117. To counter this, agonist mAbs to
costimulatory TNFR superfamily members such as CD134 (OX40), CD137 (4-1BB), GITR and
CD27 133,134,279,280 have been developed that are therapeutic in pre-clinical mouse models and
currently undergoing testing in human cancer clinical trials.
Combining immunomodulatory mAbs within the same class can augment therapeutic
outcomes. For example, since anti-CTLA-4 and -PD-1/PD-L1 are generally thought to act during
distinct early and late stages of the antitumor response, respectively 62,276,281, it is perhaps not
surprising that combining the two checkpoint inhibitors boosts therapeutic response compared to
either alone 106,110. We found over a decade ago that combining anti-CD134 plus -CD137 elicits
robust CD8 CTL responses and tumor immunity 147,148, a result confirmed by others and in
multiple systems 150,151. Importantly, this CD134 CD137 "dual costimulation" also programs
CD4 T cells to develop cytotoxic tumor cell killing potential 131, as well as deliver potent
therapeutic help 266. Thus, dual costimulation induces key antitumor responses.
While cancer immunotherapy is clearly moving towards the implementation of
combination therapies, there are regulatory complexities involved in approval for multi-agent
clinical testing 282, as well as increased potential for adverse events 106,110,282. Although 2-drug
combination therapies are being tested clinically (e.g., 106,107,110,243), and CD134 CD137 dual
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costimulation is in Phase 1 (NCT02315066), combinations involving three or more agents may
have even greater efficacy 150,152,283. Thus, a major limitation is the lack of novel approaches to
combination therapy that avoid complex mixtures of reagents. Here, we have addressed this
scientific gap by covalently linking CD134 and CD137 agonists into a single drug platform,
termed “OrthomAb”, which not only retains the costimulatory activity of the unlinked agonists,
but additionally programs unique T cell functions and preferentially expands effector T cells
over Tregs. Importantly, OrthomAb also elicits therapeutic tumor immunity in an aggressive
melanoma model. This approach provides a blueprint for distilling complex combination
immunotherapies into more clinically-feasible delivery approaches.

2. Results
OrthomAb was synthesized by conjugating anti-CD134 with anti-CD137 using MTz and TCO
couplers that were attached to the mAbs at an optimized 7:1 ratio (Figure 3.2A) via click
chemistry 284. SDS-PAGE indicated that the conjugation reaction contained heterodimers (~300
kDa), higher-order multimers and residual monomers (Figure 3.2B). The heterodimers were
enriched by three successive rounds of FPLC size-exclusion chromatography using Sephacryl
300 (Figure 3.2C-E) to yield a final OrthomAb product that was >90% dimer (Figure 3.2F).
To test if OrthomAb costimulates T cells, C57BL/6 (B6) splenocytes were stimulated in
vitro with a very low concentration of soluble anti-CD3 mAb (50 ng/ml) that only partially
induced CD25 (Figure 3.4). Importantly, addition of OrthomAb to the cultures (1.25 g/ml)
substantially increased CD25 expression on both CD4 and CD8 T cells (Figure 3.4A), and also
increased proliferation (CellTrace Violet dilution) of conventional CD4 and CD8 T cells in a
dose-dependent manner (Figure 3.4B, upper and middle panels). Strikingly, however, Treg
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proliferation appeared to be inhibited by OrthomAb (Figure 3.4B, lower panels), which
prompted further analysis of the effect of OrthomAb and unlinked costimulators on the different
T cell subsets. In contrast to conventional T cells that express CD134 and CD137 following TCR
stimulation, Foxp3+ Tregs constitutively express CD134 and CD137, and agonists to both can
impact Treg expansion and function 285-288. Unlinked CD134 and CD137 agonists individually,
as well as in combination, augmented the expansion of anti-CD3-stimulated Foxp3+ Tregs,
whereas at the doses used only anti-CD137 and the unlinked combination boosted Foxp3neg
(conventional) CD4 and CD8 T cell expansion (Figure 3.4C). Notably, although OrthomAb
boosted the expansion of conventional CD4 T cells beyond that elicited by unlinked CD137
agonist and the unlinked combination, it actually elicited weaker Treg expansion in comparison
to the unlinked combination (Figure 3.4C, bottom panel). CellTrace proliferation analysis
revealed that OrthomAb, but not unlinked single and dual costimulators, actually inhibited antiCD3-induced Treg cell division (Figure 3.4D, E). The net outcome of this effect of OrthomAb
on the different T cell subsets was an increased ratio of Foxp3neg effector T cells to Foxp3+ Tregs
with OrthomAb compared to unlinked single and dual agonists (Figure 3.4F).
A key clinical consideration is the capacity of OrthomAb to impact the amount and type
of cytokine secreted by stimulated T cells. This was first tested using Rag-/- OT-I TCR transgenic
CD8 T cells stimulated in vitro with cognate SIINFEKL peptide (Figure 3.5). OrthomAb
addition to the SIINFEKL-stimulated cell cultures elicited significantly greater secretion of IL-2
and IFN- compared to isotype control IgG, a control conjugate of irrelevant specificity, or
media alone (Figure 3.5A). Secondly, in a titratable manner, OrthomAb augmented secretion of
IL-2, IFN- and, unexpectedly, IL-6 (Figure 3.5B). Further, we tested the individual
costimulators against OrthomAb for cytokine production (Figure 3.6A, B) and CD25 expression
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(Figure 3.6C), and the data show that OrthomAb induced responses far beyond anti-CD134 or CD137. Similarly, OrthomAb elicited much higher levels of IFN-, IL-6 and IL-17 secretion
from soluble anti-CD3-stimulated B6 splenocytes compared to unlinked anti-CD134 and -CD137
(Figure 3.7A), and curiously, only OrthomAb elicited IL-6 secretion in the absence of anti-CD3
(Figure 3.7B, bottom panel). Furthermore, OrthomAb elicited much greater secretion of IFN-,
IL-6 and IL-17 from soluble anti-CD3-stimulated B6 splenocytes compared to the unlinked antiCD134 plus anti-CD137 combination (Figure 3.7C) Finally, OrthomAb, but not unlinked antiCD134 plus anti-CD137 combination, elicited IL-10 secretion with or without anti-CD3
stimulation (Figure 3.7D). OrthomAb’s enhanced cytokine response was also found to be
mediated through both CD4 and CD8 T cells (Figure 3.8). These data suggest that OrthomAb
has a unique capacity to influence not only proliferation but also the amount and type of cytokine
produced, which may prove efficacious during a biological response.
Next, the aggressive B16-F10 (B16) melanoma model 289 was used to examine if
OrthomAb could costimulate T cells in vivo and elicit antitumor immunity. In the first study,
mice harboring established B16 tumors were treated with OrthomAb (150 g) or control
conjugate on day 3 (after tumors became visible) and then again on day 6 (Figure 3.9A).
OrthomAb reduced tumor size relative to the control, with statistically significant differences on
days 4-6, 9 and 10, and reduced overall tumor burden (area under the curve 290), through day 13
(Figure 3.9B). Analysis of TIL on day 18 revealed that the percentages of CD8+ and CD4+ TIL
that were double-positive for the cytolytic granule protein granzyme B (GzmB) and the T-box
transcription factor Eomesodermin (Eomes) that programs CTL function 291 were ~2-fold higher
(p<0.001) with OrthomAb compared to control-treated tumors (Figure 3.9C). In a second
experiment, mice with established B16 tumors were treated with OrthomAb, anti-CD134, anti-
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CD137 or control IgG on days 2 (after tumors became visible), 5 and 8 (Figure 3.9D). At doses
used, monotherapy with the individual costimulators elicited, at best, only modest reductions in
tumor growth (Figure 3.9E) as quantified by tumor size at day 14 (Figure 3.9F) or area under
the curve through day 14 (Figure 3.9G). In contrast, OrthomAb significantly reduced tumor
burden ~2-fold (Figure 3.9E-G) and extended survival compared to control IgG (Figure 3.9H).

3. Discussion
Combination immunotherapies can more effectively treat cancer compared to monotherapies
106,110

, and increasing the number of agents included in these therapeutic cocktails can further

boost efficacy 110,150,152,283. Nevertheless, this approach, while feasible in mouse models, poses
various challenges for human clinical translation, including regulatory complexities involved in
approval for multi-agent clinical testing 282. The OrthomAb approach provides a means to
streamline combination immunotherapy by covalently joining two separate agents, CD134 and
CD137 agonists, into a single drug platform. Ultimately, this approach could be replicated by
conjugating other agents that, when administered with OrthomAb, would in essence distill a 4drug combination therapy into a simpler 2-drug combination. This would be advantageous in
several ways, including reducing the number of clinical trial arms.
In contrast to other well-established dual-specific immunotherapeutics, such as bispecific
antibodies that bind a tumor surface antigen (CD20, EpCAM, HER2, or others) as well as CD3
to enable tumor cell killing by tethering CTL to tumor cells 292, OrthomAb is a tetravalent
heteroconjugate comprised of mAb agonists to two separate costimulatory receptors that are each
expressed on T cells. This might co-cluster CD134 and CD137 within the same synapse,
initiating a unique or "hybrid" downstream signal that programs unexpected, but potentially
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useful, T cell functions (illustrated in Figure 3.1, and further explored in Chapter 4). This
possibility is consistent with our current findings that OrthomAb elicits greater secretion of the T
cell effector cytokines IFN- and IL-17 compared to unlinked CD134 and CD137 single and dual
mAb agonists. Alternatively, simply multimerizing individual agonists may be sufficient to
augment costimulatory activity. Nevertheless, OrthomAb was unique in its ability to elicit IL-6
secretion, even in the absence of TCR stimulation. Given that IL-6 is known to inhibit Treg
stability and function 293-296, this result might also help to explain another unexpected property of
OrthomAb, which is its ability to favor the expansion of effector T cells over Tregs (in
comparison to unlinked dual agonists). This effect appears fortuitous given that a major issue in
developing T cell-based immunotherapies is the potential of modalities to promote the expansion
of effector T cells while minimizing that of Tregs, particularly given that both use IL-2 as a
growth factor, and thus likely contributes to the ability of OrthomAb to elicit better antitumor
efficacy compared to the individual unlinked agonists. Ultimately, the mechanisms underlying
these responses elicited by OrthomAb may be highly complex given that multiple T cell and
non-T cell populations express CD134 and CD137, and hence the responses of certain cell types
may be the consequence of either direct effects by OrthomAb or indirect effects mediated by
other responding cells. These ideas will be explored further in Chapters 4 and 5.
In sum, fusing two anti-cancer biologics into a single drug platform provides a novel
blueprint for distilling complex combination therapies into a smaller number of therapeutic
agents, thus simplifying clinical translation.

4. Figures
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Figure 3.1: Proposed mechanism of OrthomAb
(A) Costimulation therapy with anti-CD134 (left panel) or anti-CD137 (middle panel) can bolster
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a patient’s antitumor immune response, but single-agonist therapy often falls short of generating
a sufficient result. Dual costimulation (DCo) combination therapy (right panel) provides a much
more potent effect and can help mount a more substantial tumoricidal response that can be
synergistic, especially when co-expressing cells are being targeted. (B) OrthomAb’s dual
specificity and multi-valency can likely promote even greater costimulatory receptor clustering
and colocalization (middle and right panels). This may drive greater signaling strengths that lead
to enhanced tumoricidal responses (middle panel) or potentially trigger a hybrid signaling
cascade that unleashes novel antitumor responses (right panel).
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Figure 3.2: OrthomAb synthesis and purification
(A) Schematic depicting click conjugation of anti-CD134 and -CD137. (B) Non-reducing SDSPAGE showing species at different stages of synthesis, with the two right-most lanes showing a
representative unpurified reaction product mixture. Chromatographic tracing of A280 versus
time (C) and SDS-PAGE (D) indicate the species present in each fraction. (E) Chromatographic
tracings with SDS-PAGE image overlays depicting species present at each purification round for
a representative triple-purified OrthomAb batch, with calculated yields shown at each step. (F)
Representative SDS-PAGE showing purified OrthomAb dimer.
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Figure 3.3: Optimization of purity and yield by fine-tuning click chemistry
(A) Non-reducing SDS-PAGE showing the effect that linker-to-mAb ratio has on final products
resulting from a representative conjugation reaction. Linker-to-mAb ratios for coupled species
are shown for methyltetrazine-PEG5-NHS ester (MTz) and anti-CD134 (left third), and transcyclooctene-PEG4-NHS ester (TCO) and anti-CD137 (middle third). Final species present after
conjugation of coupled mAbs using different linker-to-mAb ratios are shown in the rightmost
third of the gel. (B) Tracings of representative initial size-exclusion chromatography rounds
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during purification of products obtained from conjugation reactions using the indicated linker-tomAb ratios. Theoretical yields are calculated by dividing the A280 area under the curve for only
those fractions that contain appreciable quantities of OrthomAb dimer and would be pooled for
subsequent purification steps (dashed box) by the total A280 area under the curve.
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Figure 3.4: OrthomAb augments effector T cell activation and expansion
B6 splenocytes (1 x 105) were incubated with 0 or 50 ng/ml (A) or 20 ng/ml (B) soluble antiCD3 mAb +/- OrthomAb. (A) Surface CD25 expression on CD8+ and CD4+ T cells at 24 hours
post anti-CD3 stimuation +/- OrthomAb (1.25 μg/ml). (B) Anti-CD3-stimulated splenocytes
labeled with CellTrace Violet were costimulated with 0, 0.2 or 2 μg/ml OrthomAb, and cell
division (CellTrace dilution) of CD8+, CD4+Foxp3neg, and CD4+Foxp3+ T cells measured at 72
hours. Data shown are representative of multiple similar experiments. In a separate experiment
(C-F), B6 splenocytes (1 x 105) were labeled with CellTrace Violet and cultured 72 hours with
15 ng/ml soluble anti-CD3 and control IgG (2 g/ml), anti-CD134 (2 g/ml), anti-CD137 (2
g/ml), anti-CD134 plus anti-CD137 (1 g/ml each) or OrthomAb (2 g/ml), n=4 per group. (C)
Total numbers of CD8+, CD4+Foxp3neg, and CD4+Foxp3+ T cells. (D) CellTrace dilution
histogram overlays for cultures treated with soluble anti-CD3 (black) or soluble anti-CD3 plus
OrthomAb (red). (E) Division Index and % Divided CD4+Foxp3+ Tregs were calculated using
FlowJo Proliferation Tool. (F) Ratio of effector T cells (CD3+CD8+ + CD3+CD4+Foxp3neg) to
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regulatory T cells (CD3+CD4+Foxp3+). *, **, *** and **** indicate p<0.05, 0.01, 0.001 and
0.0001, respectively, compared to the control or delineated group (One-way ANOVA).
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Figure 3.5: OrthomAb boosts cytokine secretion by peptide-stimulated CD8 T cells
OT-I Rag KO splenocytes (1 x 105) were cultured 24 hours with SIINFEKL (SFKL) peptide at
50 pg/ml (A) or the indicated concentrations (B) plus 2 g/ml isotype control IgG, control
conjugate or OrthomAb. (A) Supernatant IL-2 and IFN- measured by ELISA, mean +/- SD,
n=2-4, representative of at least 3 independent, similar experiments. (B) Supernatant IL-2, IFN-,
and IL-6 with the indicated SFKL peptide and OrthomAb concentrations.
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Figure 3.6: OrthomAb boosts cytokine secretion more effectively than anti-CD134 or -CD137
OT-I Rag KO splenocytes (1 x 105) were cultured 48 hours with SFKL peptide and costimulators
at the indicated concentrations. (A) Supernatant IFN-, IL-6, and IL-17 with titrated
concentrations of SFKL peptide and costimulators. (B) Supernatant IFN-, IL-6, and IL-17
pooled from the 30 pg/ml SFKL peptide plus 0.2, 0.6, and 2.0 g/ml costimulator wells in (A).
(C) CD25 expression on OT-I CD8+ T cells. Data are representative of multiple similar trials.
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Figure 3.7: OrthomAb potently boosts cytokine secretion by anti-CD3-stimulated T cells
B6 splenocytes (1 x 105) were cultured with soluble anti-CD3 at 15 ng/ml (A), 0, 5 or 20 ng/ml
(B, D) or 20 ng/ml (C) plus the indicated concentrations of costimulators for 48 h (A, C), 24 h
(B), or 72 h (D). Significance between OrthomAb and anti-CD134 or -CD137 are indicated by *
and #, respectively (A, B); significance between OrthomAb and unlinked anti-CD134 plus CD137 are indicated by * (C, D). N=3 in each panel, which are representative of multiple similar
trials.

64

Figure 3.8: OrthomAb-treated T cells demonstrate enhanced CD4 and CD8 cytokine responses
Intracellular IFN- production by 4 h PMA + Ionomycin-stimulated CD8+ (A-C) and Foxp3neg
CD4+ (D-F) T cells amongst unpurified splenocytes following 24 (B, E, left panels) or 48 h (A,
D; B, E, right panels; C, F) culture of 1 x 105 C57BL/6 splenocytes stimulated with 15 ng/ml
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anti-CD3 plus 2.0 g/ml (A, B; D, E) or plus 0, 0.02, 0.06, 0.2, 0.6, or 2.0 g/ml (C, F) control
IgG, anti-CD134, anti-CD137, anti-CD134 plus anti-CD137, or OrthomAb). (A, D) IFN-
staining of CD8+ (A) and Foxp3neg CD4+ (D) T cells, with percentages of IFN-+ cells indicated
above gates. (B, E) IFN- histogram overlays (normalized to modes) for CD8+ (B) and Foxp3neg
CD4+ (E) T cells. (C, F) Titration curves showing percentages of IFN-+ CD8+ (C) and Foxp3neg
CD4+ (F) T cells. Data representative of at least 3 independent, similar experiments.
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Figure 3.9: OrthomAb demonstrates therapeutic efficacy in B16 melanoma
(A) Female C57BL/6 mice were injected intra-dermally with 1 x 105 B16-F10 melanoma cells
on day 0. When tumors became visible on day 3, mice were administered 150 g isotype control
conjugate (Control) or OrthomAb intra-peritoneally (indicated by first arrow beneath x-axis).
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Identical treatment boosters were administered in the same manner on day 6 (indicated by second
arrow beneath x-axis). Tumor sizes were measured daily until day 18, when tumors had reached
~200mm2 and all mice were sacrificed and TIL isolated for flow cytometric analysis. (B) Daily
tumor sizes (mm2), determined by multiplying together the longest diameter and the
corresponding perpendicular diameter. Data is shown up to day 14 post-tumor inoculation. (C)
Graphical representation showing percentage of CD8+ (top panel) and CD4+ (bottom panel) TIL
that were GzmB+ Eomes+, measured by flow cytometry. (D) In an independent experiment,
female C57BL/6 mice were injected intra-dermally with 1 x 105 B16-F10 melanoma cells on day
0. When tumors became visible on day 2, mice were administered 150 g control IgG, antiCD134, anti-CD137, or OrthomAb intra-peritoneally. Identical treatment boosters were
administered in the same manner on days 5 and 8. Tumor sizes were measured every 1-2 days
until mice reached a pre-defined endpoint (tumor size > 250 mm2 or moribundity), which
occurred between days 15 and 32. (E) Individual tumor growth curves (mm2), determined by
multiplying together the longest diameter and the corresponding perpendicular diameter. Data is
shown up to day 14 post-tumor inoculation. (F) Scatter plot of day 14 tumor sizes (mm2). (G)
Scatter plot of area under the curve (AUC) values calculated up to day 14. (H) Survival curves
for control IgG-treated mice and OrthomAb-treated mice.
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Chapter 4. Exploring the Mechanisms of OrthomAb and Dual Costimulation Synergy

1. Does OrthomAb involve simultaneous colocalization of CD134 and CD137?
Dual costimulation (DCo) is a particularly potent combination therapy, synergistically boosting
CD8+ T cell clonal expansion and effector function 148, as well as inducing differentiation of
cytotoxic CD4+ Th1 cells 131. The mechanism by which these two pathways converge to program
highly tumoricidal T cells, however, is not yet fully understood. Although OrthomAb and DCo
both target CD134 and CD137, they likely differ in terms of how they engage the receptors and
the quantity and quality of signaling they impart. DCo consists of two distinct antibodies (i.e.,
“unlinked” combination therapy). This means that one of the antibodies is equally capable of
binding to a cell that expresses only that antibody’s target receptor as it is to binding to a cell that
expresses both receptors. One consequence of this relates to the fact that some therapeuticallyirrelevant cells can express low levels of one of the receptors (CD137 in particular), which can
get bound by antibody and trigger immune attack and collateral damage244,246,247. These “ontarget, off-tumor” interactions contribute to the overall toxicity that occurs during treatment.
On the other hand, some immune cells may get costimulated by one of the antibodies but
not the other, either because that cell happens to express one receptor only (e.g., CD134 and
CD137 expression kinetics and cellular distributions do not overlap completely), or because
individual mAbs are not necessarily confined in proximity and are free to bind independently of
the other. It is possible that synergistic activity observed with DCo treatment is the result of
costimulation through CD134 and CD137 strictly on cells expressing both receptors, as depicted
in Figure 3.1; if this was the only mechanism driving DCo synergy, then, ideally, only cells
expressing both receptors would be bound and costimulated by anti-CD134 and anti-CD137.
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However, this is not the only mechanistic scenario that could manifest as DCo synergy. It is
possible that synergy does not require co-expressing T cells to be costimulated by both mAbs.
For example, cellular interactions between anti-CD137-costimulated dendritic cells and antiCD134-costimulated T cells could drive a much stronger effector response than would occur
with anti-CD134 or anti-CD137 monotherapy alone. There also is the possibility that multiple
mechanisms are at play, and each one contributes differently to the overall synergy.
OrthomAb’s structure may confer unique biological activity that is not observed with
DCo. The click chemical linkage ensures that both constituent antibodies are kept in close
proximity to one another, which should preferentially focus dual costimulation onto
CD134/CD137 co-expressing cells. This receptor binding pattern is referred to as “cis-acting”
(illustrated in Figure 3.1B). This would be a major advantage if simultaneous costimulation of
both receptors on the same cell is the primary (or sole) mechanism of synergy. Another
advantage is that this should limit some of the undesirable “on-target, off-tumor” effects that can
happen with unlinked DCo therapy. Another plausible mechanism of OrthomAb involves a type
of binding pattern known as “trans-acting”. For instance, the anti-CD137 part of OrthomAb
could bind a dendritic cell while the anti-CD134 portion of OrthomAb binds a T cell; in this
case, OrthomAb would costimulate both cells and also serve as a tether, pulling the two cells
closer together and promoting enhanced interaction and greater activation.
In order to investigate these questions, we bred the following mice:
•

CD134-/- mice on C57BL/6 background and on OT-I Rag-/- background

•

CD137-/- mice on C57BL/6 background and on OT-I Rag-/- background

•

CD134-/-CD137-/- (DKO) mice on C57BL/6 background and on OT-I Rag-/background
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We first confirmed that the single and double knockout mice had no obvious anatomical or
developmental abnormalities, with normal spleens and thymuses, and T cell subset distributions
that are consistent with WT mice (Figure 4.1). To determine if OrthomAb co-ligates CD134 and
CD137 on the same T cell (i.e., cis-acting) or, alternatively, if co-ligation occurs between
adjacent T cells expressing one or the other receptor (i.e., trans-acting), we performed in vitro T
cell stimulation assays comparing OrthomAb’s potentiation of cytokine secretion from
SIINFEKL-stimulated OT-I CD8+ T cells that are:
1)

WT (positive control where both cis and trans co-ligation can occur)

2)

CD134/CD137 double KO (negative control where neither cis nor trans ligation can
occur)

3)

CD134 single KO (only CD137 can be ligated)

4)

CD137 single KO (only CD134 can be ligated)

5)

Co-culture of CD134 single KO with CD137 single KO (only trans co-ligation can
occur)

We also measured surface expression levels of CD134, CD137, and CD25; differential
expression of the CD45 congenic marker allowed us to distinguish between the CD134 and
CD137 single KO OT-I cells during flow cytometric analysis.
After a 48-hour stimulation with SIINFEKL peptide only, the single knockout cells
demonstrated a diminished ability to upregulate CD25, even when co-cultured together (Figure
4.2A). Interestingly, the CD134 KO cells expressed CD137 at lower levels than WT, and the
CD137 KO cells expressed CD134 at much lower levels than WT (Figure 4.2A). OrthomAb
treatment substantially increased expression of CD25 on WT cells, but CD25 expression was
decreased by about half on the CD134 KO cells. The CD137 KO cells did not express CD25
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when cultured alone, but they were able to when co-cultured with the CD134 KO cells (Figure
4.2B). Cytokine secretion from single KO cells was also substantially impaired relative to WT
cells, especially at the lower SIINFEKL concentrations, and co-culturing the cells did not rescue
their ability to secrete cytokine (Figure 4.2C). These results suggested that only cis co-ligation
(i.e., on the same T cell) is important mechanistically to OrthomAb’s in vitro activity.
A follow-up study revealed that DCo’s activity was also severely blunted with CD134
and CD137 single KO cells; intriguingly, co-culturing the single KO cells did not rescue IFN secretion or CD25 expression for either DCo or OrthomAb (Figure 4.3). These data suggest
that cis co-ligation is necessary for both OrthomAb and DCo to exhibit synergy in vitro.
Once we had DKO mice, we were able to compare them to the single KO mice and WT
mice. During a 12 or 24 h culture with SIINFEKL and DCo, CD134 KO and CD137 KO cells
expressed slightly lower levels of CD25 than did WT cells, and DKO expression levels of CD25
were the lowest (Figure 4.4A). Strikingly, however, IFN- secretion was massively reduced in
both single KOs and DKO cells (Figure 4.4B). These data suggest that loss of one receptor is as
detrimental as the loss of both receptors, at least with regard to in vitro IFN- secretion from
CD8+ OT-I cells. In other words, for both DCo and OrthomAb, cis-acting dual costimulation of
T cells appears to be the predominant mechanism of synergy driving CD8+ T cell cytokine
potentiation.
Additional in vitro experiments planned for the more distant future involve culturing
purified T cells from WT or single-KO mice (alone or co-cultured) with purified APCs from
DKO mice. These experiments will offer more insight into whether synergy involves only coexpressing T cells, or if, for example, the presence of CD137 on activated dendritic cells
contributes at all to synergy.

72

Subsequent in vivo experiments will involve adoptively transferring the same OT-I CD8+
T cells just described into syngeneic, WT recipient mice immunized with SIINFEKL plus
OrthomAb. In vivo readouts will be performed using splenocytes 5 days post-immunization and
will include clonal expansion and intracellular expression of the cytotoxic effector molecule
granzyme B (GzmB) and the T-box transcription factors T-bet and Eomesodermin (Eomes)
directly ex vivo, as well as the tumoricidal cytokines IFN- and TNF- following in vitro
restimulation with SIINFEKL 131,148,297,298. In co-transfer experiments, CD134 and CD137 single
KO OT-I cells can be distinguished from each other and from the endogenous non-specific CD8+
T cells through the differential expression of the CD45 congenic marker, as they were in coculture experiments. It is important to keep in mind that there is always the possibility that we
will observe different outcomes in vitro versus in vivo, in which case we will need to modify in
vitro assay conditions to more accurately reflect in vivo responses (e.g., alter the culture density
or the accessory cell composition). This will be important for certain mechanistic studies, and
future translational studies using human T cells where, outside of clinical trials, in vivo response
assays are not feasible.
Lastly, CD134/CD137 single- and double-KO mice will be used in tumor challenge
experiments. WT, CD134 KO, CD137 KO, or DKO mice (all on the C57BL/6 background) will
be inoculated with B16 melanoma and treated with DCo or OrthomAb, either in the same
experiment or in separate experiments. Antitumor efficacy will be evaluated as in Figure 3.9.
Another important tumor challenge experiment will involve adoptively transferring OT-I CD8+ T
cells from the single- and double-knockout (or WT) OT-I mice into syngeneic, WT (C57BL/6)
recipient mice inoculated with B16-OVA and immunized with SIINFEKL plus OrthomAb or
DCo. Single-KO cells will also be co-transferred to see if any loss of efficacy can be rescued.
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This experimental tumor challenge setup will use T cell activation functional readouts (as
described above); antitumor efficacy will also be assessed as in Figure 3.9.

2. Does OrthomAb engage a hybrid signaling pathway?
Because of OrthomAb’s dual-specificity and multi-valency, cis-binding might simultaneously
co-localize and cluster both receptors within the same synapse, allowing their subunits to interact
in a non-physiological context. This, in turn, could influence signaling events to unlock hybrid
costimulation programs, ultimately generating unique functional responses. A hybrid signaling
mechanism could explain not only OrthomAb’s potency, but also some of its unique properties
such as IL-6, IL-17, and IL-10 secretion (Figure 3.6, Figure 3.7), as well as its differential
effects on Treg proliferation (Figure 3.4).
To explore whether OrthomAb engages hybrid signaling, we generated homodimers of
CD134 and CD137 (Figure 4.5). Future experiments will test these new reagents using in vitro
assays similar to those we have used previously, and then comparing them to OrthomAb in terms
of cytokine secretion and T cell proliferation. The combination of both homodimers (CD134
homodimer + CD137 homodimer) will be vital to compare to OrthomAb. If only OrthomAb
elicits some of the “atypical” cytokines such as IL-6, IL-10, and IL-17, then that would support
the hypothesis that OrthomAb’s mechanism is unique and functions through hybrid signaling.
We will also use a more direct approach to study intracellular signaling. TNFR ligation
mediates costimulatory function via engagement of various combinations of six separate TNF
receptor-associated factors (TRAF1-6) that assemble signaling complexes that activate
downstream kinases and transcription factors such as JNK and NFB 299. Although there is
overlap in the TRAF combinations used by various TNFRs, they are not identical. For example,
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CD134 and CD137 have been reported, in varying degrees and in different models, to engage
TRAFs 1, 2, 3, 5, and 6 300-304, and TRAFs 1, 2, and 3 300,301, respectively. We do not know
which TRAFs are engaged by OrthomAb, and whether this combination represents the
summation of both agonists or hybrid signaling that may fuse both pathways.
To analyze the signaling pathways induced by OrthomAb, standard in vitro costimulation
assays used previously will be modified as follows: since early costimulatory signaling events
will be measured, and naïve T cells lack CD134 and CD137, cell cultures will be pre-stimulated
overnight with anti-CD3 or SIINFEKL to induce receptor expression, antigen presenting cells
with potential to express the natural ligands will be removed using MHC class II-conjugated
magnetic beads, and the T cells will be rested in fresh media for 3 h to allow costimulatory
signaling to return to baseline. Next, T cells will be treated with OrthomAb, IsomAb or media
alone (negative controls), unlinked CD134 and/or CD137 agonists (to determine signaling
associated with the individual pathways), or CD134 and/or CD137 homodimers (to determine
the effect of dimerization). Phosphorylation of JNK and IB (upstream of NF-B) will be
measured at 0, 5, 10, 15, 30 and 60 min, association of TRAF1-6 with the receptors will be
measured at 10 min via co-immunoprecipitation, and TRAF degradation will be measured at 5 h
as previously described 305.
Whether or not OrthomAb engages downstream signaling distinct from unlinked dual
costimulation will be important to know to help guide future mechanistic studies. OrthomAb
may engage the sum of signaling events elicited by each individual agonist, but our preliminary
data are suggestive of signaling events not seen with either alone or in combination. It is possible
that differences in signaling may reflect quantitative, rather than qualitative, differences in
receptor ligation. One last thing worth noting is that TRAFs and their associated pathways might
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not be the best readout for hybrid signaling. If this turned out to be the case, a non-biased
proteomics approach could be helpful in identifying other ways to address the issue of hybrid
signaling.

3. Figures
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Figure 4.1: CD134 and CD137 knockout mouse spleen and thymus characterization
Thymocytes (left panel) and splenocytes (right panel) were harvested from WT, CD134-/-,
CD137-/-, or CD134-/-CD137-/- (DKO) mice, all on the C57BL/6 background. Harvested cells
were then stained for flow cytometric analysis to determine cellular phenotypes and T cell subset
distributions. Plots are gated on live, single cells (left) or live, single, CD4+, CD8neg cells (right).
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Figure 4.2: Costimulatory receptor-knockout OT-I splenocytes exhibit diminished in vitro
activity and impaired response to OrthomAb treatment
Splenocytes were obtained from WT (black line), CD134KO (blue line), or CD137KO mice (red
line), all on OT-I RagKO background, and 1 x 105 OT-I cells were cultured for 48 h with the
indicated concentrations of SIINFEKL peptide (SFKL) +/- OrthomAb. (A) Expression of
CD134, CD137, and CD25 on cells cultured with peptide only; dashed lines and "*" indicate that
cells were co-cultured at a 1:1 ratio. (B) CD25 expression on cells cultured at the indicated SFKL
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concentrations +/- different OrthomAb concentrations. (C) Supernatant cytokine levels obtained
at 48 h from the cultures described in A & B; knockout co-cultures are indicated with purple,
dashed lines. N = 1, representative of multiple experiments.
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Figure 4.3: CD134/CD137 knockout cells are less responsive to DCo and to OrthomAb
Splenocytes were obtained from WT, CD134-/-, or CD137-/- mice (all on OT-I Rag-/- background),
and 1 x 105 OT-I cells were cultured with 5, 10, or 15 pg/ml SIINFEKL peptide (SFKL) +/- Rat
IgG, DCo or OrthomAb. Supernatant IFN-g levels (left) and OT-I cell surface expression of
CD25 (right) were measured after 48 h culture. In the left panel, “KO + KO” indicates that
supernatant was collected from wells that contained both single-knockout cell types at a 1:1
ratio. In the right panel, "*" indicates cells that were co-cultured, but that could be gated on
analysis to determine CD134-/- and CD137-/- cell type expression levels separately. N = 3.
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Figure 4.4: Similar functional impairments are observed with single- and double-KO mice
Splenocytes were obtained from WT, CD134-/-, CD137-/-, or CD134-/-CD137-/- (DKO) mice (all
on OT-I Rag-/- background), and 1 x 105 OT-I cells were cultured with 10 or 20 pg/ml SIINFEKL
peptide plus 0.2 g/ml DCo. (A) CD8+ T cell surface expression of CD25 before culture, and
after 12 or 24 h culture. (B) Supernatant IFN- levels after 12 or 24 h culture. N = 1 of multiple
pooled culture wells (A), or n = 3 comprised of culture triplicates (B).
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Figure 4.5: CD134 and CD137 homodimers
Homodimers of anti-CD134 and of anti-CD137 were generated using a similar protocol that was
used to make OrthomAb (refer to Figure 3.2). (A) Cartoon depictions of OrthomAb (top), antiCD134 homodimer (middle), and anti-CD137 homodimer (bottom). Note that click linkages are
identical in all three. (B) SDS-PAGE showing anti-CD134 and anti-CD137 monomers (2 left
lanes), next to each of the homodimers and OrthomAb (middle lanes), and rat IgG (last lane).
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Chapter 5. Developing a Next-generation OrthomAb Engineered to Limit Toxicity

1. Generate and test a modified OrthomAb that lacks Fc domains
As already discussed extensively in Chapter 1, a major cause of adverse events occurring with
immunotherapeutic mAb therapy is the crystallizable fragment (Fc), which interacts with Fc
receptors (FcR) on innate cells (e.g., monocytes, NK cells) and can drive massive release of proinflammatory cytokines 162,164,169,170,306,307 (Figure 1.1C, Figure 5.1A). Additionally, coating of
therapeutically-irrelevant cells expressing the target receptors can lead to antibody-dependent
cellular cytotoxicity or phagocytosis (ADCC or ADCP)-mediated collateral damage 244-247
(Figure 1.1D, Figure 5.1A). Moreover, FcR could potentially mediate ADCC/ADCP directed
toward costimulated T cells, thereby limiting efficacy.
Although the procedure is trivial to remove Fc domains from antibodies using the
enzyme pepsin, doing so generally abrogates efficacy because it is the Fc domains that
orchestrate the FcR-mediated clustering of mAb-bound receptors that initiate costimulatory
signaling 9,190,208-210.
However, there have been reports of FcR-independent costimulatory activity, suggesting
that Fc requirements are not absolute 192,211,216,254,263. In particular, antibody multimerization has
been shown to be an effective strategy to bypass FcR requirements of anti-CD40 agonist while
preserving activity in vitro and in vivo, as well as in a model of lymphoma with FcR-knockout
mice 254.
Similarly, OrthomAb’s multivalent structure raises the possibility that its therapeutic
activity does not require FcR, suggesting that a modified OrthomAb lacking Fc will retain
activity, without triggering FcR-mediated toxicity caused by innate cell activation and cytokine
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storm 1,169,252,306 (Figure 5.1C). An added benefit is that the activity of Fc-less OrthomAb would
not be reliant on FcR availability, which can vary substantially between different tissues,
fluctuate based on immune status (e.g., recent infection), is prone to patient-to-patient differences
in Fc-FcR binding avidities and ratios of activating to inhibitory FcRs, and can further be
influenced by FcR-SNPs in patients 1,253,308-312.
Fc-less OrthomAb is synthesized using the same protocol used to make OrthomAb (as in
Figure 3.2), with the following modification: Fc domains from CD134 agonist (clone OX86,
IgG1) and CD137 agonist (clone 3H3, IgG2a) are digested with pepsin to generate F(ab’)2
fragments 313-315 prior to click coupling and conjugation. Figure 5.2A is a schematic showing the
protocol for Fc-less OrthomAb synthesis. We first had to carefully optimize pepsin digestion
conditions for each mAb (Figure 5.2B) before scaling up the reactions to obtain CD134 and
CD137 F(ab’)2 fragments, clicking them together and isolating Fc-less OrthomAb (Figure 5.2C).
Note that lane 5 of the SDS-PAGE gel in Figure 5.2C contains Fc-less OrthomAb that has been
enriched with only a single round of size-exclusion chromatography. Nevertheless, this initial
Fc-less OrthomAb batch was tested for costimulatory activity in vitro. Indeed, this Fc-less
reagent induced IFN- secretion with a potency comparable to that of standard OrthomAb
(Figure 5.2D).
In follow-up experiments, we will confirm this result using new Fc-less OrthomAb dimer
preparations purified through multiple FPLC rounds (as with standard OrthomAb in Figure 3.2).
These experiments will also test the activity of the unclicked F(ab’)2 monomers, which we
expect will lack optimal costimulatory capacity (as previously observed with anti-CD137 316),
even when combined and added at high concentrations, since they can cluster at most only 2
receptors. If observed, this result would indicate that Fc-less OrthomAb does indeed possess Fc-
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independent costimulatory capacity.
Next, the in vivo immunotherapeutic potential of Fc-less OrthomAb will be assessed
using the aggressive B16-F10 melanoma model 289 that we have used previously to test
OrthomAb 268 (Figure 3.9) and to study unlinked DCo 131,297,298. If Fc-less OrthomAb does
exhibit therapeutic activity, we will then assess its ability to act in an Fc-independent manner by
testing the unlinked anti-CD134 and anti-CD137 F(ab’)2 monomers given in combination. If they
are therapeutically inert (in contrast to the active Fc-containing monomers), this would indicate
that linking the F(ab’)2 fragments indeed bypasses the necessity for Fc to effectively cluster the
receptors.
A central facet of our hypothesis is that removal of the Fc domains will reduce toxicities
and adverse events elicited by OrthomAb (Figure 5.1C). This idea will be tested in the B16
model by measuring serum levels of pro-inflammatory cytokines associated with cytokine
release syndrome, such as TNF-, IL-6, IL-1, MCP-1, and others 169,252,306, as well as liver
enzymes indicative of hepatic damage 107,306,317. Thus, even if standard OrthomAb and Fc-less
OrthomAb control tumor growth to similar extents, our hypothesis would be supported if Fc-less
OrthomAb elicits lower serum levels of pro-inflammatory cytokines and liver enzymes from
organ damage.

2. How do OrthomAb and Fc-less OrthomAb impact intratumoral Tregs?
A surprising aspect of immunomodulatory mAbs that has emerged recently is that they not only
boost the response of tumor-specific effector T cells but can also mediate therapeutic efficacy by
altering the function of T regulatory cells (Tregs) residing within the tumor microenvironment.
For instance, both anti-CTLA-4 78,197,198 and CD134 agonist 318 have been shown to delete
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intratumoral Foxp3+ Tregs via FcR-dependent mechanisms that likely involve ADCC or ADCP.
On the other hand, CD137 agonist programs Tregs to acquire cytotoxic potential 319. We also
recently found that although unlinked DCo reduces the frequency of intratumoral Tregs (similar
to CD134 agonist given alone 318), the remaining Foxp3+CD4+ T cells acquire certain
characteristics of effector T cells (expression of GzmB, IFN- and Eomes) and perhaps aid the
therapeutic response 298. We have not yet determined whether this effect involves Treg depletion,
or alternatively whether DCo induces intratumoral Tregs to undergo reprogramming to become
effector T cells 320. Importantly, we do not know whether this effect depends on Fc-FcR
interactions, which is a critical consideration given that Fc-less OrthomAb is designed to avoid
Fc-FcR interactions.
Future studies will use the "exFoxp3" fate mapping approach developed by Bluestone
and colleagues 200 to determine whether Fc-less OrthomAb induces deletion of intratumoral
Tregs, or alternatively reprograms them to differentiate into effector T cells. Briefly, transgenic
mice expressing a GFP-Cre fusion protein from the Foxp3 locus will be crossed to mice that
contain a stop-floxed tdTomato reporter within the constitutive ROSA locus, such that CD4+ T
cells actively expressing Foxp3 (Foxp3+GFP+TOM+) can be distinguished from exFoxp3 cells
that previously expressed Foxp3 (Foxp3negGFPnegTOM+). The crossed double transgenic mice
will be given B16 tumors and then treated with unlinked CD134 plus CD137 agonists, standard
OrthomAb, Fc-less OrthomAb or corresponding isotype or IsomAb controls.
Analysis of the exFoxp3 mice will indicate how unlinked DCo reduces intratumoral Treg
frequency while inducing expression of GzmB and Eomes in the remaining Tregs 298. In control
(IgG-treated) mice we expect to observe a high intratumoral frequency of Tregs but very few
exFoxp3 cells. If unlinked DCo diminishes Treg frequency without increasing exFoxp3 cells,
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this would indicate that DCo depletes a portion of intratumoral Tregs, while inducing the
remaining Tregs to express Eomes and GzmB. This possibility would be consistent with both the
observation that CD134 agonist can induce Treg deletion 318 and that Tregs can gain effector
capacity while maintaining Foxp3 expression 294,321. Alternatively, if exFoxp3 cell frequency
increases, this would indicate that DCo induces Treg reprogramming.
Standard (Fc-containing) OrthomAb may elicit a similar effect as unlinked DCo
(regardless of the mechanism revealed), given that both have the capacity to bind costimulatory
receptors as well as FcR. If the mechanism is shown to involve Treg reprogramming (i.e.,
generation of exFoxp3 cells), and Fc-less OrthomAb also mediates this effect, this result would
suggest that reprogramming only requires costimulatory receptor clustering on the Tregs.
Alternatively, if Treg deletion is induced by DCo and standard OrthomAb, it may not occur with
Fc-less OrthomAb given that Treg deletion would likely involve Fc-FcR interactions 78,197,198,318.
These results will be integrated into a fuller understanding of how costimulation elicits
therapeutic tumor immunity and further inform us how to best improve subsequent generations
of OrthomAb.

3. Figures
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Figure 5.1: Preventing FcR-mediated toxicity with Fc-less OrthomAb
(A) Combining elements of Figure 1.1 and Figure 3.1, this model illustrates the intra- and extra-
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cellular interactions driving the efficacy and adverse events due to FcR engagement that occur
during unlinked DCo therapy. (B) Since OrthomAb is made from whole antibodies, it has two Fc
domains that still likely have the ability to interact with FcR located on adjacent FcR-expressing
cells, which could trigger some of the same adverse events that occur with unlinked DCo. (C)
Removal of the Fc domains of anti-CD134 and anti-CD137 prior to click coupling and
conjugation enables the synthesis of an “Fc-less” OrthomAb, which should have efficacy
comparable to that of OrthomAb, but would avoid FcR-related toxicity.
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Figure 5.2: Synthesis of Fc-less OrthomAb
(A) Cartoon depicting synthesis of Fc-less OrthomAb. (B) SDS-PAGE showing species present
following pepsin digestion of anti-CD134 or anti-CD137 at pH 4.0 for various durations at 37
degrees celcius. (C) SDS-PAGE showing initial mAbs, Fc-less mAbs (F(ab’)2) following 24 h
(anti-CD134) or 13 h (anti-CD137) digestion, and then clicked Fc-less OrthomAb dimer
enriched once by size-exclusion chromatography (purple arrow). (D) Supernatant IFN-
following 24 h culture of C57BL/6 splenocytes stimulated with 20 ng/ml anti-CD3 plus titrated
dosages of Fc-less OrthomAb, standard OrthomAb and individual agonists; n=3.
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Chapter 6. Conclusions and Future Directions

Cancer is the 2nd leading cause of death in the United States, afflicting over one-third of
the population and killing half of those diagnosed 322. Discovery of the immune system’s
intrinsic ability to recognize and kill tumor cells spurred an explosion of interest and quickly
became a major focus of investigation; not too long thereafter, immunomodulatory antibodies
have brought about a revolution in cancer therapy. Patient success stories continue to make
headlines, and results from ongoing clinical trials have provided us with an ever-expanding body
of evidence highlighting that there is new hope in the fight against this terrible disease.
Thus far, however, these agents as monotherapies have had limited success in curing all
but subsets of patients. This is likely due to the existence of not one, but several
immunosuppressive mechanisms employed by tumors to avoid elimination by the immune
system. Response rates can be improved by combining therapies that target multiple
immunosuppressive pathways 106,110,243, but translation is impeded by regulatory complexities
involved in the approval process for multi-agent clinical trials 282,323, in addition to increased
rates and severity of adverse events 106,282. These barriers to clinical translation currently limit the
feasibility of multi-targeted approaches.
Taking a step back, the idea for OrthomAb began as a relatively simple one: CD134
agonist works pretty well…CD137 agonist works pretty well too…CD134 agonist plus CD137
agonist works really well…what would happen if CD134 agonist and CD137 agonist were
covalently linked…? This question is what I have spent the last 4 years of my life thinking about.
On the one hand, it might seem as though OrthomAb was a novel and intriguing idea that
inspired a “throw it against the wall and see what sticks” type of approach without any precisely-
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defined hypotheses. On the other hand, it might seem possible that the goal of making OrthomAb
was to be able to ask whether “OrthomAb is better than DCo”. I came to appreciate that making
OrthomAb eventually served to simultaneously test multiple different, albeit overlapping,
hypotheses, and that there exist several possible, non-mutually-exclusive, reasons that OrthomAb
will ultimately prove to be a worthwhile science experiment after all.
At the core of this project are two overarching ideas or themes that OrthomAb tested:
1) Combination therapy bundled into a single drug
• Conjugating two immunotherapeutics into a single biologic offers the
benefits of combination therapy while also avoiding the logistical
complications involved in simultaneous co-administration of multiple
unlinked monotherapies.
2) FcR-independent efficacy
• OrthomAb should enable removal of Fc domains while preserving the
ability to cluster costimulatory receptor subunits to induce a therapeutic
response without triggering FcR-mediated toxicity.
Additional questions and ideas gradually surfaced along the way. For example, the fact
that OrthomAb targets two different (yet similar) TNFR family members (i.e., CD134 and
CD137) opened the possibility that hybrid signaling might be taking place, which might elicit
unique functions that may or may not be advantageous. Sure enough, our data suggest this likely
may be the case (Figure 3.4, Figure 3.6, Figure 3.7, Figure 4.2). Evidence strongly supports the
argument that OrthomAb is valuable therapeutically. Importantly, the “value” of OrthomAb in
relation to unlinked DCo would, in this case, be a matter of quality rather than quantity; this is
just one example of how asking the question of whether “OrthomAb is better than DCo” is much
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more complex than simply comparing magnitudes of response readouts.
A more detailed summary of the conceptual advances that may be revealed and better
understood with continued studies on the OrthomAb platform include the following:
1) OrthomAb links two drugs (CD134 agonist and CD137 agonist), each targeting distinct
pathways, into one drug. This will simplify translation and clinical implementation of
DCo combination therapy
2) OrthomAb should preferentially engage co-localized CD134 and CD137 on
therapeutically-relevant cells (i.e., T cells), in contrast to standard, unlinked DCo, which
can also target therapeutically-irrelevant cells expressing only one of the targets (e.g.,
endothelia that express CD137 244,246,247) and trigger collateral damage
3) Simultaneous and co-localized CD134/CD137 costimulation may involve intermingling
between the subunits of both receptor types within the same synapse, which may initiate
hybrid downstream signaling and potentially lead to unique biological responses with
increased efficacy
4) OrthomAb’s multivalent structure raises the possibility that its therapeutic activity does
not require FcR interactions, suggesting that a modified OrthomAb lacking Fc domains
could retain costimulatory activity without triggering FcR-mediated toxicity from innate
cell activation and consequent cytokine storm 1,169,252,306
5) The activity of Fc-less OrthomAb would not be reliant on the local availability of FcR,
which can vary substantially between different tissues, can fluctuate based on current
immune status (e.g., recent infection), is prone to the patient-to-patient variability in Fc-
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FcR binding avidities and ratio of activating-to-inhibitory FcRs and, finally, is not subject
to FcR-SNPs in patients 1,253,308-312
6)

This work will lay a general framework for single-agent engineering of many other mAbbased combinations targeting distinct tumoricidal pathways

Looking back, the original hypothesis of my dissertation proposal nicely summarizes the
OrthomAb platform:
The overarching hypothesis is that OrthomAb will possess the
combined costimulatory capabilities and therapeutic effects of both
CD134 and CD137 agonists all in one drug, while also exhibiting a
more favorable side effect profile compared to unlinked combination
therapy

Future work will focus on understanding the mechanism(s) that underlie OrthomAb’s biological
activity, knowledge from which will guide its modification to increase its therapeutic index. One
such aspect of OrthomAb relates to the biochemical/biophysical factors that define OrthomAb’s
structure and, consequently, determine the cellular interactions that influence OrthomAb’s
mechanism(s) at a fundamental level. Further discussion related to this topic is beyond the scope
of this dissertation, but I predict that antibody engineering, which is already a well-established
and productive area of investigation 192,211,261,324-330, will become a major driving force in
advancing the field of cancer immunotherapy.
This next point has already been belabored, but it is worth reemphasizing the notion that
continued studies of OrthomAb will help lay the foundation for a solid understanding on which
to build the next generation of “single-agent combination therapies”, as well as other
immunomodulatory agents that are optimally engineered for maximum efficacy and minimal
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toxicity.
Cancer immunotherapy is one of the most exciting and fast-moving fields in medical
science today, and it will truly be exciting to see where the future takes us. Depending on
who you ask, many people believe that we will eventually have a cure for cancer, and I
believe that it is only a matter of time before we do. Of course, it is difficult to predict when
and how we will find the cure, and what that cure will look like. I obviously don’t know the
answers to these questions. But what I can say is that my money is on future generations of
the same types of immunotherapies we have today that we are just now beginning to perfect.
And I believe that the OrthomAb platform could turn out to be one of the avenues that helps
us get there as quickly as possible.
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